<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003426.pub5" GROUP_ID="CF" ID="360301011614554967" MERGED_FROM="" MODIFIED="2016-03-04 09:27:35 +0000" MODIFIED_BY="Tracey Remmington" REVIEW_NO="0047" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2016-03-04 09:22:11 +0000" MODIFIED_BY="Tracey Remmington">
<TITLE>Drugs for preventing red blood cell dehydration in people with sickle cell disease</TITLE>
<CONTACT>
<PERSON ID="11592" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Samir</FIRST_NAME>
<MIDDLE_INITIALS>K</MIDDLE_INITIALS>
<LAST_NAME>Ballas</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Samir.Ballas@jefferson.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardeza Foundation for Hematologic Research, Department of Medicine</DEPARTMENT>
<ORGANISATION>Jefferson Medical College, Thomas Jefferson University</ORGANISATION>
<ADDRESS_1>1015 Walnut Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Philadelphia</CITY>
<ZIP>PA 19107-5099</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 215 955 8485</PHONE_1>
<PHONE_2/>
<FAX_1>+1 215 923 7859</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-03-04 09:21:28 +0000" MODIFIED_BY="Tracey Remmington">
<PERSON ID="E31A950E82E26AA2000465304963E04B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Srikanth</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Nagalla</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>srikanthnagalla@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine, Division of Hematology</DEPARTMENT>
<ORGANISATION>Thomas Jefferson University</ORGANISATION>
<ADDRESS_1>Medical Center Boulevard</ADDRESS_1>
<ADDRESS_2>1015 Walnut Street</ADDRESS_2>
<CITY>Philadelphia</CITY>
<ZIP>PA 19107-5099</ZIP>
<REGION>Pennsylvania</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11592" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Samir</FIRST_NAME>
<MIDDLE_INITIALS>K</MIDDLE_INITIALS>
<LAST_NAME>Ballas</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Samir.Ballas@jefferson.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardeza Foundation for Hematologic Research, Department of Medicine</DEPARTMENT>
<ORGANISATION>Jefferson Medical College, Thomas Jefferson University</ORGANISATION>
<ADDRESS_1>1015 Walnut Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Philadelphia</CITY>
<ZIP>PA 19107-5099</ZIP>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 215 955 8485</PHONE_1>
<PHONE_2/>
<FAX_1>+1 215 923 7859</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-03-04 09:21:52 +0000" MODIFIED_BY="Tracey Remmington">
<UP_TO_DATE>
<DATE DAY="4" MONTH="3" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="11" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="5" MONTH="3" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-03-04 09:22:11 +0000" MODIFIED_BY="Tracey Remmington">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-03-04 09:22:11 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="4" MONTH="3" YEAR="2016"/>
<DESCRIPTION>
<P>We have made only minor changes to the text throughout the review for this 2016 update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-03-04 09:22:06 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="4" MONTH="3" YEAR="2016"/>
<DESCRIPTION>
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register and 28 references were identified; however, none were eligible for inclusion in any section of the review.</P>
<P>We will continue to run searches to identify any potentially relevant trials; however, we do not plan to update other sections of the review until new trials are published.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-01-15 10:17:01 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-01-15 10:16:59 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>A new study has been included in the review but did not lead to a change in conclusions (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-01-15 10:17:01 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>A search of the Group's Haemoglobinopathies Trials Register identified 34 references of which one has been listed as an included study (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>) and three as excluded studies (<LINK REF="STD-Bartolucci-2009" TYPE="STUDY">Bartolucci 2009</LINK>; <LINK REF="STD-Gladwin-2011" TYPE="STUDY">Gladwin 2011</LINK>; <LINK REF="STD-Uzun-2010" TYPE="STUDY">Uzun 2010</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-11-29 13:07:20 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="20" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-09-20 10:16:05 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="11" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>A new lead author (SN) has updated this review with the existing co-author (SB).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-05-09 11:20:47 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="11" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>A search of the Group's Trials Register identified eight new references which were potentially eligible for inclusion in this review.</P>
<P>One new study was included in the review (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>).</P>
<P>Seven of these have been excluded; four references were additional references to already excluded studies (<LINK REF="STD-Beatty-2007" TYPE="STUDY">Beatty 2007</LINK>; <LINK REF="STD-Qari-2007" TYPE="STUDY">Qari 2007</LINK>; <LINK REF="STD-Weiner-2002" TYPE="STUDY">Weiner 2002</LINK>; <LINK REF="STD-Wynn-2007" TYPE="STUDY">Wynn 2007</LINK>); and three were references to new studies (<LINK REF="STD-Akinsulie-2005" TYPE="STUDY">Akinsulie 2005</LINK>; <LINK REF="STD-Silva_x002d_Pinto-2007" TYPE="STUDY">Silva-Pinto 2007</LINK>; <LINK REF="STD-Wallen-2007" TYPE="STUDY">Wallen 2007</LINK>).</P>
<P>Through personal communication, we have details of a Phase III trial for which publication is pending (Ballas 2009). Full details will be included in a future update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-26 09:44:02 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="4" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-11-05 11:29:19 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="19" MONTH="7" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment.<BR/>
<BR/>A new review team has updated this review. Dr Priya C. Singh is now lead author with Dr Samir K. Ballas as co-author.<BR/>
<BR/>The former lead author, Ceri Hirst (née Riddington), and former co-author Dr Lucia de Franceschi are no longer active authors on the review.<BR/>
<BR/>One trial previously included in this review has been removed (<LINK REF="STD-Piracetam-Study-1998" TYPE="STUDY">Piracetam Study 1998</LINK>). The piracetam trial was excluded since the current authors believe there is insufficient evidence that it acts primarily via the red cell membrane to improve red cell rheology.<BR/>
<BR/>The search of the Group's Haemoglobinopathies Trials Register in November 2006 identified trials possibly eligible for inclusion. Two references were to already excluded studies and these references have been added to the appropriate study IDs (<LINK REF="STD-Adams_x002d_Graves-1997" TYPE="STUDY">Adams-Graves 1997</LINK>; <LINK REF="STD-Orringer-1991" TYPE="STUDY">Orringer 1991</LINK>). One reference has been added to <LINK TAG="EXCLUDED_STUDIES" TYPE="SECTION">Excluded studies</LINK> (<LINK REF="STD-Alvim-2005" TYPE="STUDY">Alvim 2005</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-05 11:31:39 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="1" MONTH="6" YEAR="2004"/>
<DESCRIPTION>
<P>The search of the Group's trials register identified eight new references, however, none were found to be eligible for inclusion in the review.</P>
<P>Five references to three newly identified studies have been excluded. Details of these studies can be found in the <LINK TAG="EXCLUDED_STUDIES" TYPE="SECTION">Excluded studies</LINK> section of the review (<LINK REF="STD-Adams_x002d_Graves-1997" TYPE="STUDY">Adams-Graves 1997</LINK>; <LINK REF="STD-Al_x002d_Jam_x0027_a-1999" TYPE="STUDY">Al-Jam'a 1999</LINK>; <LINK REF="STD-Godeau-2003" TYPE="STUDY">Godeau 2003</LINK>; <LINK REF="STD-Jacobson-1997" TYPE="STUDY">Jacobson 1997</LINK>; <LINK REF="STD-Pace-2003" TYPE="STUDY">Pace 2003</LINK>).</P>
<P>Three references identified were to two already excluded studies (<LINK REF="STD-Ataga-2002" TYPE="STUDY">Ataga 2002</LINK>; <LINK REF="STD-Wambebe-2001" TYPE="STUDY">Wambebe 2001</LINK>). These additional references have been added to the appropriate study IDs.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-05 11:31:13 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="1" MONTH="7" YEAR="2003"/>
<DESCRIPTION>
<P>Five new studies have been identified for inclusion within the <LINK TAG="EXCLUDED_STUDIES" TYPE="SECTION">Excluded studies</LINK> section of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-09-03 22:56:18 +0100" MODIFIED_BY="Tracey Remmington">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-09-03 22:56:18 +0100" MODIFIED_BY="Tracey Remmington">
<SOURCE MODIFIED="2015-09-03 22:56:18 +0100" MODIFIED_BY="Tracey Remmington">
<NAME>National Institute for Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-03-04 09:22:51 +0000" MODIFIED_BY="Tracey Remmington">
<SUMMARY MODIFIED="2016-01-28 14:36:38 +0000" MODIFIED_BY="Tracey Remmington">
<TITLE>Drugs that aim to reduce the loss of water from red blood cells in people with sickle cell disease</TITLE>
<SUMMARY_BODY MODIFIED="2016-01-28 14:36:38 +0000" MODIFIED_BY="Tracey Remmington">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence to assess the relative risks and benefits of drugs to rehydrate sickled red blood cells.</P>
<P>
<B>Background</B>
</P>
<P>Sickle cell disease is an inherited condition that causes red blood cells to become sickle shaped when they lose water. This leads to a high risk of the blood vessels becoming blocked. Such blockages can cause pain, stroke and damage to organs. Recent therapies aim to stop the cells becoming sickle shaped by preventing them losing water.</P>
<P>
<B>Search date</B>
</P>
<P>The evidence is current to: 28 November 2015.</P>
<P>
<B>Study characteristics</B>
</P>
<P>The review included three studies with 524 people with sickle cell disease aged between 12 and 65 years of age. The intervention in one study was zinc sulphate and in two studies was senicapoc. Each study was compared to a placebo group (a substance which contains no medication). For each study people were selected for one treatment or the other randomly. The studies lasted from three months to 18 months.</P>
<P>
<B>Key results</B>
</P>
<P>The study with zinc sulphate showed that this drug may be able to reduce the number of sickle cell crises without causing toxic effects. There were 145 participants in this study and results showed a significant reduction in the total number of serious sickle-related crises over one and a half years, mean difference -2.83 (95% confidence interval -3.51 to -2.15). However, our analysis was limited since not all data were reported. Changes to red cell measurements and blood counts were not consistent. No serious adverse events were noted in the study. The two studies with senicapoc demonstrated that this drug increases the red blood survival and has a role in the prevention on red blood cell dehydration in people with sickle cell disease. The higher dose of the drug was more effective compared to the lower dose. But these changes in the red blood cells did not translate into positive clinical outcomes in terms of reduction in the number of sickle cell crises. Senicapoc had a favourable safety profile. More longer-term research is needed on these drugs and others that might prevent water loss in red blood cells.</P>
<P>We will continue to run searches to identify any potentially relevant trials; however, we do not plan to update other sections of the review until new trials are published.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>All the studies appeared to be well run and we do not think any factors will influence the results in a negative way.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-01-28 14:36:16 +0000" MODIFIED_BY="Tracey Remmington">
<ABS_BACKGROUND MODIFIED="2015-05-07 13:50:33 +0100" MODIFIED_BY="[Empty name]">
<P>Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells. These are rigid and may block blood vessels leading to acute painful crises and other complications. Recent research has focused on therapies to rehydrate the sickled cells by reducing the loss of water and ions from them. Little is known about the effectiveness and safety of such drugs. This is an updated version of a previously published review.<BR/>
</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-09-17 13:22:07 +0100" MODIFIED_BY="Nikki Jahnke">
<P>To assess the relative risks and benefits of drugs to rehydrate sickled red blood cells.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-01-28 14:30:45 +0000" MODIFIED_BY="Tracey Remmington">
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register.</P>
<P>Last search of the Group's Trials Register: 28 November 2015.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-11-04 14:35:50 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Randomized or quasi-randomized controlled trials of drugs to rehydrate sickled red blood cells compared to placebo or an alternative treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-09-17 13:28:48 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Both authors independently selected studies for inclusion, assessed study quality and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-04-26 15:19:13 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Of the 51 studies identified, three met the inclusion criteria. The first study tested the effectiveness of zinc sulphate to prevent sickle cell-related crises in a total of 145 participants and showed a significant reduction in painful crises over one and a half years, mean difference -2.83 (95% confidence interval -3.51 to -2.15). However, analysis was restricted due to limited statistical data. Changes to red cell parameters and blood counts were inconsistent. No serious adverse events were noted in the study.</P>
<P>The second study was a Phase II dose-finding study of senicapoc (a Gardos channel blocker) compared to placebo. Compared to the placebo group the high dose senicapoc showed significant improvement in change in hemoglobin level, number and proportion of dense red blood cells, red blood cell count and indices and hematocrit. The results with low-dose senicapoc were similar to the high-dose senicapoc group but of lesser magnitude. There was no difference in the frequency of painful crises between the three groups. A subsequent Phase III study of senicapoc was terminated early since there was no difference observed between the treatment and control groups in the primary end point of painful crises.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-01-28 14:36:16 +0000" MODIFIED_BY="Tracey Remmington">
<P>While the results of zinc for reducing sickle-related crises are encouraging, larger and longer-term multicenter studies are needed to evaluate the effectiveness of this therapy for people with sickle cell disease.</P>
<P>While the Phase II and the prematurely terminated phase III studies of senicapoc showed that the drug improved red cell survival (depending on dose), this did not lead to fewer painful crises.</P>
<P>We will continue to run searches to identify any potentially relevant trials; however, we do not plan to update other sections of the review until new trials are published.<BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-03-04 09:22:51 +0000" MODIFIED_BY="Tracey Remmington">
<BACKGROUND MODIFIED="2015-05-07 13:52:38 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-04-27 09:52:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Sickle cell disease is caused by the inheritance from both parents of a mutation in the beta-globin gene. The different types of the disease (e.g. SS, SC, S&#946;Thal) are caused by inheritance of different altered beta-globin genes, and this can be diagnosed with blood tests or genetic testing. It is so named because the red blood cells (erythrocytes) become distorted into unusual shapes when they give up the oxygen they carry, due to polymerisation of the abnormal hemoglobin within. This is accelerated by a cycle of red blood cell dehydration, which increases intracellular concentration of the sickle hemoglobin and hence polymerisation. One of the distinguishing features of sickle cell anemia is the presence of these dense, dehydrated red cells, which are easily destroyed and can mesh together to block blood vessels (vaso-occlusion).</P>
<P>The disease is characterised by episodes of anemia, vaso-occlusive crises and organ damage, with symptoms which are unpredictable and differ between individuals (<LINK REF="REF-Serjeant-1992" TYPE="REFERENCE">Serjeant 1992</LINK>). It is most prevalent in populations originating from sub-Saharan Africa and parts of India; although population movement has made it a world-wide problem, with approximately 60,000 African-American and 10,000 British people with the disease (<LINK REF="REF-Davies-1997" TYPE="REFERENCE">Davies 1997</LINK>; <LINK REF="REF-Hickman-1999" TYPE="REFERENCE">Hickman 1999</LINK>). Clinical management centers around prophylaxis against infection, pain relief, hydration and periodic blood transfusion in many people to reduce the concentration of sickle cells in the blood stream. However, most treatment is symptomatic and, as a result, despite vastly improving care services, many people with the disease still die in childhood due to sudden bouts of infection, stroke, acute chest syndrome or splenic sequestration (<LINK REF="REF-Leikin-1989" TYPE="REFERENCE">Leikin 1989</LINK>). Clearly preventative measures would be preferable.</P>
</CONDITION>
<THEORY MODIFIED="2012-04-26 15:22:32 +0100" MODIFIED_BY="Nikki Jahnke">
<P>In an attempt to prevent the increased concentration of sickle hemoglobin (which causes polymerisation and deformation of the red blood cell), recent research has begun to target the physiological process leading to dehydration of the erythrocyte for therapeutic potential. Red cells are thought to undergo dehydration via two kinetically distinct pathways, a "fast track" process in reticulocytes (immature red blood cells), and a slow process involving mature erythrocytes. Dehydration via either pathway is due to the water loss accompanying primary loss from the cell of potassium and chloride ions. The major routes involved in sickle cell dehydration are the calcium-activated potassium channel (Gardos channel) operating in parallel with the conductive chloride pathway and the electroneutral potassium-chloride co-transporter(s) (<LINK REF="REF-Brugnara-1995" TYPE="REFERENCE">Brugnara 1995</LINK>). Potential therapeutic approaches involve the use of drugs that reduce sickle cell dehydration via a block of these mechanisms.</P>
<P>The first route, and perhaps the most promising for therapy, is the Gardos channel. Upon deoxygenation of the sickle cell, potassium and water loss are induced as free intracellular calcium levels rise, possibly due to increased membrane permeability for calcium. The Gardos channel may also be positively modulated by vaso-active molecules such as endothelins (<LINK REF="REF-Rivera-2000" TYPE="REFERENCE">Rivera 2000</LINK>). Studies both in a mouse model for sickle cell disease (SAD mouse) and in humans have shown that this channel can be selectively inhibited by a group of drugs known as the imidazole antimycotics, including the anti-fungal agent clotrimazole (<LINK REF="REF-Brugnara-1993" TYPE="REFERENCE">Brugnara 1993</LINK>; <LINK REF="REF-Brugnara-1996" TYPE="REFERENCE">Brugnara 1996</LINK>; <LINK REF="REF-de-Franceschi-1994" TYPE="REFERENCE">de Franceschi 1994</LINK>) and a related compound Senicapoc (ICA-17043) (<LINK REF="REF-Stocker-2000" TYPE="REFERENCE">Stocker 2000</LINK>). Blocking of the Gardos channel resulted in increased potassium content and improved hydration of erythrocytes. Senicapoc (bis(4-fluorophenyl)phenyl acetamide) is a selective and potent blocker of the Gardos channel (<LINK REF="REF-Stocker-2003" TYPE="REFERENCE">Stocker 2003</LINK>). Dimethyl adipimate may also have an anti-sickling role via the Gardos channel (<LINK REF="REF-Gibson-2000" TYPE="REFERENCE">Gibson 2000</LINK>).<BR/>
<BR/>The role of the chloride conductance or exchange system in sickle cell dehydration has also been recently explored. In vitro, loss of potassium from deoxygenated human sickle cells could be limited by the reversible anion conductance inhibitor NS1652 (<LINK REF="REF-Bennekou-2000" TYPE="REFERENCE">Bennekou 2000</LINK>). Further, the related compound, NS3623 (<LINK REF="REF-Bennekou-2001" TYPE="REFERENCE">Bennekou 2001</LINK>), which has a greater half-life in vivo, improved hydration in the SAD mouse.</P>
<P>Potassium-chloride co-transport occurs via a different membrane protein, which is activated by acidity within the cell allowing loss of potassium and water. This is seen almost exclusively in reticulocytes. No drugs have been found to be useful in inhibiting the transporter, but it has been shown that divalent cations, such as magnesium ions (<LINK REF="REF-Brugnara-1987" TYPE="REFERENCE">Brugnara 1987</LINK>), can block the pathway, again protecting against dehydration. Magnesium preparations are currently marketed for treatment of constipation, boils, recurrence of seizures in eclampsia, renal failure and are recommended for emergency treatment of serious arrhythmias. Magnesium pidolate has been investigated in combination with hydroxyurea in a Phase I trial (<LINK REF="REF-Hankins-2008" TYPE="REFERENCE">Hankins 2008</LINK>).</P>
<P>Other strategies have also been suggested for reducing sickle red cell dehydration. These include a transmembrane sodium-potassium pump mechanism which is partly responsible for increased ion permeability on deoxygenation. While this is thought to be a minor contributor to dehydration, dipyridamole has been shown to be a selective inhibitor of passive ion transfer and there is rationale, including the known effects on platelet and endothelial cell function, for testing its efficacy in sickle cell disease. Oxidative damage to the cell membrane, which can occur in sickle cell disease due to abnormal iron deposits, increases loss of potassium and water contributing to red cell dehydration (<LINK REF="REF-Brugnara-1995" TYPE="REFERENCE">Brugnara 1995</LINK>). Oral iron chelators may help in this case, and antioxidants could also be useful (<LINK REF="REF-Gibson-1998" TYPE="REFERENCE">Gibson 1998</LINK>). Nitric oxide, an endogenous compound which is thought to be an important regulator of smooth muscle tone and vasodilatation, is reduced in people with sickle cell disease (<LINK REF="REF-Qureshi-2000" TYPE="REFERENCE">Qureshi 2000</LINK>). Preliminary studies in SAD mice have shown that it can reduce red cell dehydration (<LINK REF="REF-Adrie-2000" TYPE="REFERENCE">Adrie 2000</LINK>), and oral supplementation with arginine, an amino acid which releases nitric oxide, (5% by weight) also induces a decrease in red cell density (<LINK REF="REF-Romero-2000" TYPE="REFERENCE">Romero 2000</LINK>), via Gardos channel activity (<LINK REF="REF-Romero-2002" TYPE="REFERENCE">Romero 2002</LINK>). Hydroxyurea, an anti-cancer compound proven to reduce sickle-related events (<LINK REF="REF-Charache-1995" TYPE="REFERENCE">Charache 1995</LINK>; <LINK REF="REF-Jones-2001" TYPE="REFERENCE">Jones 2001</LINK>), improves the hydration status of sickle red blood cells (<LINK REF="REF-Ballas-1989" TYPE="REFERENCE">Ballas 1989</LINK>), although it is not clear whether this is a direct effect, or a consequence of increased levels of fetal hemoglobin (HbF).</P>
<P>In Brazil a local plant, <I>Pfaffia paniculata</I>, has been anecdotally reported to ameliorate clinical symptoms of sickle cell disease. The plant possibly contains a naturally occurring compound, which acts as a sodium ionophore. '<I>In vitro</I>' studies have shown increased erythrocyte deformability and sodium content of sickle red cells when treated with it, thus potentially rehydrating sickle cells (<LINK REF="REF-Ballas-2000" TYPE="REFERENCE">Ballas 2000</LINK>).</P>
<P>Piracetam (2-oxo-1-pyrrolidine acetamide), a derivative of the neurotransmitter gamma-aminobutyric acid (GABA), works primarily in neurotransmission, but appears to have a beneficial effect on red cell rheology and thus able to reduce vaso-occlusive crises in people with sickle cell disease. The exact mechanism of this remains unclear. It does not appear to inhibit the Gardos channel as previously reported (<LINK REF="REF-Gini-1987" TYPE="REFERENCE">Gini 1987</LINK>; <LINK REF="REF-Stone-1988" TYPE="REFERENCE">Stone 1988</LINK>; <LINK REF="REF-Stuart-1990" TYPE="REFERENCE">Stuart 1990</LINK>; <LINK REF="REF-Stuart-1992" TYPE="REFERENCE">Stuart 1992</LINK>). The use of piracetam for reducing the incidence of painful sickle cell disease crises is the subject of another Cochrane Review (<LINK REF="REF-Al-Hajeri-2007" TYPE="REFERENCE">Al Hajeri 2007</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-05-07 13:52:38 +0100" MODIFIED_BY="[Empty name]">
<P>All of these potential therapies look promising for reducing dehydration of red blood cells, and therefore ameliorating the symptoms of sickle cell disease. This review aims to bring together clinical trials in this area to establish the clinical value of this pharmaceutical approach.</P>
<P>This is an update of previously published versions of the review (<LINK REF="REF-Nagalla-2010" TYPE="REFERENCE">Nagalla 2010</LINK>; <LINK REF="REF-Nagalla-2012" TYPE="REFERENCE">Nagalla 2012</LINK>; <LINK REF="REF-Riddington-2002" TYPE="REFERENCE">Riddington 2002</LINK>; <LINK REF="REF-Singh-2007" TYPE="REFERENCE">Singh 2007</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-04-27 09:53:02 +0100" MODIFIED_BY="Tracey Remmington">
<P>To determine whether pharmaceutical therapies designed to prevent red cell dehydration in sickle cell disease:</P>
<OL>
<LI>reduce mortality;</LI>
<LI>reduce sickle cell vaso-occlusive crises including episodes of pain and stroke;</LI>
<LI>reduce other complications associated with sickle cell disease e.g. acute chest syndrome, infection, anemia, splenic sequestration, organ damage;</LI>
<LI>are associated with unacceptable adverse events.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2016-01-28 14:32:04 +0000" MODIFIED_BY="Tracey Remmington">
<SELECTION_CRITERIA MODIFIED="2016-01-28 14:32:04 +0000" MODIFIED_BY="Tracey Remmington">
<CRIT_STUDIES MODIFIED="2009-11-04 14:35:53 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Randomized or quasi-randomized trials. Trials in which quasi-randomized methods, such as alternation, are used were included if there was sufficient evidence that the treatment and control groups were similar at baseline.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with known sickle cell disease (SS, SC, S&#946;+ and S&#946;0, proven by electrophoresis and sickle solubility test, with family studies or DNA tests as appropriate) of all ages and both sexes, in any setting.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-11-04 14:37:09 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Pharmaceutical therapies designed to reduce red cell dehydration to prevent vaso-occlusive events in sickle cell disease compared to comparator interventions. Studies which included anti-sickling drugs for which the exact mechanism of action is not known were considered if there was some evidence that they act via the red blood cell membrane to prevent sickling. Piracetam was excluded since there is insufficient evidence that it acts primarily via the red cell membrane to improve red cell rheology. Hydroxyurea was excluded as the primary mechanism for this drug is through increasing foetal hemoglobin. Studies in which the intervention was given only to treat an existing sickle-related event were excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-01-28 14:32:04 +0000" MODIFIED_BY="Tracey Remmington">
<P>While the interventions should, by definition, decrease dense sickled cells by reducing erythrocyte dehydration, such biochemical parameters were examined separately from clinical outcomes, to determine the effectiveness of the interventions in clinical practice. However, the hematological outcomes may also provide an indication of the efficacy, and potential effectiveness, of treatment, so these were also analyzed.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<OL>
<LI>Number of deaths</LI>
<LI>Number of sickle pain crises (requirement for opiate treatment or self-reported patient scales)</LI>
<LI>Number of serious complications of sickle cell disease including stroke, acute chest syndrome and acute splenic sequestration</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<OL>
<LI>Red cell dehydration (proportion of dense cells, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV))</LI>
<LI>Full blood count including hemoglobin, white blood cell and platelet counts, sickle cell hemoglobin (HbS) and foetal hemoglobin (HbF) level</LI>
<LI>Quality of life: days off work or school, hospitalisations, mobility, etc.</LI>
<LI>Number of other sickle-related events, including priapism, leg ulceration</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other outcomes</HEADING>
<OL>
<LI>Any reported adverse effects or toxicity of drugs were recorded</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-01-28 14:31:03 +0000" MODIFIED_BY="Tracey Remmington">
<ELECTRONIC_SEARCHES MODIFIED="2016-01-28 14:31:03 +0000" MODIFIED_BY="Tracey Remmington">
<P>Relevant studies were identified from the Cystic Fibrosis &amp; Genetic Disorders Review Group's Haemoglobinopathies Trials Register using the terms: (sickle cell OR (haemoglobinopathies AND general)) AND (dehydration OR (anti-sickling OR crisis).</P>
<P>The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of <I>The Cochrane Library</I>) and weekly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html">Cystic Fibrosis and Genetic Disorders Group Module</A>.</P>
<P>Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 28 November 2015.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-05 11:40:31 +0000" MODIFIED_BY="Tracey Remmington">
<P>The bibliographic references of all retrieved literature were reviewed for additional reports of studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-04-27 09:54:12 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY_SELECTION MODIFIED="2009-05-26 09:47:11 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Two authors independently applied the inclusion criteria in order to select studies for inclusion in the review. If disagreement arose on the suitability of a study for inclusion in the review, the authors reached consensus by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-05-26 09:47:31 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Two authors independently extracted the data. Each author, using standard data acquisition forms, independently extracted data. If disagreement arose on the study quality, the authors reached a consensus by discussion.</P>
<P>We planned to collect data at monthly time-frames. However, if data were reported at other time periods we planned to consider examining these as well.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-08-12 13:18:00 +0100" MODIFIED_BY="Tracey Remmington">
<P>Two authors assessed the risk of bias of each study. In particular, authors examined details of the randomization method, allocation concealment, whether the study was blinded, whether intention-to-treat analyses were possible from the available data and if the number of participants lost to follow up or subsequently excluded from the study was recorded.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-11-05 11:45:59 +0000" MODIFIED_BY="Tracey Remmington">
<P>We recorded dichotomous outcomes e.g. life or death, as present or absent, whilst recording continuous data such as organ function tests as either mean change from baseline for each group or mean post treatment values and standard deviation (SD) for each group. We aimed to calculate a pooled estimate of the treatment effect for each outcome across studies, (for binary outcomes the odds of an outcome among treatment allocated participants to the corresponding odds among controls).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-11-04 15:28:09 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Cross-over trials will only be included in future versions of this review if we consider there to be a sufficient washout period between the treatment arms. We will analyze any data from such trials according to methods described by Elbourne (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-11-05 11:45:26 +0000" MODIFIED_BY="Tracey Remmington">
<P>We sought full reports from authors where studies have been published in abstract form, presented at meetings or reported to the co-authors. Where information was missing or unclear, we contacted the primary investigator.</P>
<P>In order to allow an intention-to-treat analysis, we grouped data by allocated treatment groups, irrespective of later exclusion (regardless of cause) or loss to follow up.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-09-14 15:18:59 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We will test for heterogeneity between studies using a standard chi-squared test and I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We will use the following ranges to describe heterogeneity:</P>
<UL>
<LI>0% to 40%: might not be important;</LI>
<LI>30% to 60%: may represent moderate heterogeneity;</LI>
<LI>50% to 90%: may represent substantial heterogeneity;</LI>
<LI>75% to 100%: considerable heterogeneity.</LI>
</UL>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-09-17 11:07:18 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Comprehensive searches were done by both the authors to minimize publication and reporting biases. We compared the 'Methods' section of the full published paper to the 'Results' section to ensure that all outcomes which were measured, were reported.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-09-17 10:58:20 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We have used fixed-effect analysis with the data we have presented. If there is a high or moderate degree of heterogeneity between studies included in any future updates, we will consider using a random-effects analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-11-04 15:28:45 +0000" MODIFIED_BY="Nikki Jahnke">
<P>If we find heterogeneity between studies, examination of subgroups, such as age of participants, type of sickle cell disease or ethnicity, may help to explain the reasons for this.</P>
<P>For future updates, where appropriate, we plan to perform subgroup analysis of different drugs or combinations of drugs to examine their relative risks and benefits.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-04-27 09:54:12 +0100" MODIFIED_BY="Nikki Jahnke">
<P>If we include a sufficient number of studies where quasi-randomization methods are used, we will analyze this group separately.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-03-04 09:22:51 +0000" MODIFIED_BY="Tracey Remmington">
<STUDY_DESCRIPTION MODIFIED="2016-01-28 14:31:12 +0000" MODIFIED_BY="Tracey Remmington">
<P> </P>
<SEARCH_RESULTS MODIFIED="2011-11-29 13:21:55 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Fifty-one studies of anti-sickling agents were identified from the searches. Three studies were included within the review (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>; <LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>; <LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-01-28 14:31:12 +0000" MODIFIED_BY="Tracey Remmington">
<SUBSECTION>
<HEADING LEVEL="4">Trial design</HEADING>
<P>All three studies were described as double-blind, randomized placebo-controlled studies (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>; <LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>; <LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>). The Phase II Ataga study was a dose-finding study which compared a 10 mg dose of senicapoc to a 6 mg dose of senicapoc or to placebo. The trial was multicenter (19 medical centers) in the United States of America (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). The study treated participants for 12 weeks (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>).The recent senicapoc trial was a Phase III trial was conducted across 75 centers in 6 countries (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). The participants were randomized to senicapoc (20 mg twice daily as a loading dose for 4 days followed by 10 mg daily) or placebo in a 1:1 fashion. The treatment phase consisted of 52 weeks followed by a follow-up period of 8 weeks (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). The Gupta trial was from a single center in India (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>). The Gupta study lasted for one and a half years; participants were seen weekly but data were analysed at the end of the follow-up period (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>There were 524 participants with sickle cell disease included in the review. The Phase II senicapoc study randomized 90 participants aged between 18 to 60 years (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). The Phase III senicapoc study randomized 297 participants between the ages of 16 and 65 years, but only the 289 participants in the modified intent-to-treat group (participants who received at least one dose of the drug) were included in this review (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). In the remaining study, Gupta randomized 145 participants aged between 12 to 27 years (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
<P>In the Phase II senicapoc study, participants had at least one episode of sickle cell-related painful crisis four weeks prior to the study screening and participants taking hydroxyurea had to be on a stable dose of the drug for at least three months prior to their enrolment in the study (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). In the Phase III senicapoc study, participants had at least two episodes of painful crisis within the preceding 12 months that required medical attention (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). Participants on hydroxyurea in preceding 12 months were required to be on a stable dose of the drug prior to inclusion in the study (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). Gupta excluded participants under five years of age or those who had a history of chronic persistent infection, evidence of organ failure, exposure to extreme temperatures or were taking other medication (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
<P>In the Phase II senicapoc study, all the participants who received at least one week of the drug and underwent the initial efficacy analysis were included in the modified intent-to-treat analysis. Eighty-eight participants met this criteria and only two discontinued the study before the initial efficacy analysis (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). In the Phase III senicapoc study 289 participants from the initial group of 297 were included in the modified intent-to-treat analysis based on participants who received at least one dose of the drug (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). However, in the Gupta study, 15 participants out of the original 145 subsequently dropped out or were lost to follow-up, and these were not included in the analysis (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>The Phase II senicapoc study compared three groups: high-dose senicapoc (single 150 mg loading dose followed by 10 mg daily maintenance dose); or low-dose senicapoc (single 100 mg loading dose followed by 6 mg daily maintenance dose); or placebo (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). The high-dose senicapoc group had 31 participants, the low-dose senicapoc and placebo groups had 29 and 30 participants assigned respectively. The Phase III senicapoc study stratified participants based on concomitant hydroxyurea therapy. In each of these groups participants were randomized to receive senicapoc (loading dose of 20 mg twice daily for four days followed by 10 mg daily) or placebo in a 1:1 fashion. Out of the 289 participants in the modified intent-to treat analysis, there were 163 participants in the hydroxyurea group and 126 in the non-hydroxyurea group. The hydroxyurea group had 84 participants receiving senicapoc and 79 participants on placebo. The non-hydroxyurea group had 61 senicapoc participants and 65 in the placebo group (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). The third study randomized participants to receive either zinc sulphate (220 mg three times a day orally) or an identical placebo (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes measured</HEADING>
<P>The Ataga Phase II study reported the effect of senicapoc on hemoglobin levels, red blood cell (RBC) indices, markers of hemolysis and painful crises. The primary end point of the study was the change in hemoglobin level with the secondary end points being changes in the number and proportion on the dense red blood cells (RBCs) and reticulocytes, lactate dehydrogenase, indirect bilirubin, RBC count, RBC indices, hematocrit and frequency of painful crises (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). The primary end point in the Ataga Phase III was the frequency of sickle cell pain crises. TIme to the first, second and third acute painful crises was a secondary end point of the study (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). The effect of the drug on markers of hemolysis, hemoglobin, hematocrit, reticulocyte count, red blood cell count and dense erythrocytes were also measured. The Gupta study measured the number of sickle-related crises, and the number of days in hospital and working (or school) days lost for each crisis (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-11-29 13:19:26 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Forty-eight studies were excluded. Reasons for exclusions were a lack of evidence that they were acting primarily on red cell dehydration pathways, or they were being used to treat a sickle-related crisis, rather than preventing it, or the study was not randomized (<I>see</I> <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table). Studies on piracetam were excluded since there is insufficient evidence that this drug acts primarily via the red cell membrane to improve red cell rheology (<LINK REF="STD-Alvim-2005" TYPE="STUDY">Alvim 2005</LINK>; <LINK REF="STD-Piracetam-Study-1998" TYPE="STUDY">Piracetam Study 1998</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-05-07 13:46:31 +0100" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2012-04-27 09:54:21 +0100" MODIFIED_BY="Nikki Jahnke">
<P>All three studies were judged to have a low risk of bias for the generation of the allocation sequence (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>; <LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>; <LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>). In both of the senicapoc studies an integrated voice response system was used in the centralized randomization protocol (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>; <LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). In the zinc study, New Castle software was used to generate randomization (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
<P>Both the senicapoc studies and the zinc study did not report on allocation concealment and so all studies were judged to have an unclear risk of bias for this criteria (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>; <LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>; <LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-11-29 13:22:05 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Both the participants and treating physicians were blinded in all three studies and so were judged to have a low risk of bias (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>; <LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>; <LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>). Additionally, Ataga reported that the review committee were also blinded (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-05-07 13:46:31 +0100" MODIFIED_BY="[Empty name]">
<P>In the senicapoc Phase II study, a modified intent-to-treat population was used in the efficacy analysis (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). Two out of the the 90 participants dropped out prior to the initial assessment and so 88 participants were included as a part of the modified intent-to-treat population. The safety analysis included all the 90 participants. A total of 10 participants did not complete the study; full reasons for this were given in the published paper and we therefore judged there to be a low risk of bias due to incomplete outcome data (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>).</P>
<P>The Phase III senicapoc study was terminated early due to a lack of efficacy as determined by the unblinded Data Monitoring Committee (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). The reasons for the Committee&#8217;s decision were based on the fact that there was no significant improvement in the rate of sickle cell painful crises in participants treated with senicapoc compared to those on placebo (P = 0.38 versus P = 0.31 respectively) despite improvements in anemia and hemolysis. Moreover, comparisons of the times to first, second and third crises between the senicapoc and placebo groups were not significantly different. The authors suggest that the increase in Hb level caused an increase in blood viscosity and offset the potential benefits of senicapoc with regards to painful crises. Furthermore, due to the early termination of the study, the duration that the drug was administered was different in the participants who stopped treatment early. Given these facts, we have not entered any data from this trial into the data tables and results are reported narratively.  <BR/>
</P>
<P>In the zinc study, a power calculation, which assumed 40% control event rate and 20% response, found that 130 participants were needed. Fifteen, of the 145 participants recruited, dropped out or were lost to follow-up, and these are not accounted for in the study publication (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>). We therefore judge there to be an unclear risk of bias from reported outcome data for this study.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-02-16 13:14:02 +0000" MODIFIED_BY="Nikki Jahnke">
<P>In both the senicapoc studies and the zinc study, all outcomes stated in 'Methods' section were reported in the 'Results' section of the papers; therefore there is a low risk of bias for selective reporting for all studies (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>; <LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>; <LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-04-26 15:57:35 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The participants in the Phase II senicapoc study were evenly matched in terms of their baseline characteristics between the three study arms (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>) and this was also true for the Phase III senicapoc study (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). There was no significant difference in the mean age, sex and the hospitalizations in the year prior to the enrolment in the study. We therefore judged both studies to have a low risk of bias for this domain.</P>
<P>The zinc study gave little information regarding baseline characteristics, including disease severity and medical history of participants, making it difficult to ascertain if the groups were sufficiently similar at the start of the study (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>). Thus currently we judge there to be an unclear risk of bias for this study.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-03-04 09:22:51 +0000" MODIFIED_BY="Tracey Remmington">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Number of deaths</HEADING>
<P>No treatment related deaths were reported in the included studies (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>; <LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>; <LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Number of pain crises</HEADING>
<P>In the senicapoc Phase II study there were a total of 15 sickle cell crises, with the events being distributed equally between the placebo and the two intervention arms (five in each) (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). So both the lower (6 mg) and higher doses (10 mg) of senicapoc did not help in the reduction of painful crises compared to placebo.</P>
<P>The Phase III senicapoc study was terminated prematurely as it was unlikely to meet the primary endpoint (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). There was no significant difference in the rate of the sickle cell painful crises between the senicapoc and placebo groups (0.38 versus 0.31, P = 0.054). There was no difference in the painful crises rate between the two treatment arms in the hydroxyurea group (0.39 versus 0.33, P = 0.483) but the rate of painful crises was significantly higher in the senicapoc group compared to the placebo group in participants not on hydroxyurea (0.37 versus 0.29, P = 0.037) (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). The study included pain-only crises, acute chest syndrome, hepatic sequestration, priapism and stroke under the primary end point of sickle cell-related pain crises. Given that the study was terminated prematurely, there are very few participants who completed the treatment. The duration of the drug regimen was different in the participants who stopped treatment. Therefore we have not included any data from this trial in the data analysis table.</P>
<P>In the zinc study there were 91 vaso-occlusive crises in the intervention group, compared to 220 in the control group (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>). This amounts to, on average, 1.40 and 3.38 painful crises per participant in intervention and control groups respectively. Standard deviations cannot be calculated from the data provided in the publication, so we are attempting to contact the authors, and hope to provide this information in a future update.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Number of other serious sickle-related complications</HEADING>
<P>In the Phase II senicapoc study, there were two episodes of pneumonia and one episode of bronchitis in the placebo group (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). There was one episode of pneumonia in each of the intervention arms. There was a single episode of acute chest syndrome in the study and it occurred in the 6 mg (low-dose) senicapoc arm. There was one episode of aseptic necrosis of the bone in the low-dose senicapoc arm and one episode of deep venous thrombosis in the high-dose senicapoc arm. Furthermore, there was one episode of staphylococcal sepsis in the low-dose senicapoc group and one urinary tract infection in the high-dose senicapoc group. The only case of deep vein thrombosis was reported in the high-dose senicapoc group (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>).</P>
<P>The Phase III senicapoc study included pain-only crises, acute chest syndrome, hepatic sequestration, priapism and stroke under the primary end point of sickle cell-related pain crises (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>).</P>
<P>In the zinc study, altogether there were 160 episodes of sickle-related crises in the intervention group, and 344 in the control group (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>). Of these, vaso-occlusive crises accounted for 59% in the intervention group and 64% in the control group, mixed crises for 24% and 20% in the intervention and control groups respectively, 9% and 12% were hemolytic, 1% in each group sequestration and 1% in each group had aplastic crises. The mean number of all sickle-related crises in the intervention group was 2.46 (SD 1.04), compared to 5.29 (SD 2.58), in the control group. The MD between groups was -2.83 (95% CI -3.51 to -2.15), showing a statistically significant reduction in the participants treated with zinc (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Red cell dehydration</HEADING>
<P>Both the high and low doses of senicapoc resulted in a significant decrease in the percentage of dense red blood cells compared to the placebo (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). The magnitude of decrease was higher with the 10 mg senicapoc compared to the 6 mg senicapoc. There was a significant decrease in the MCV and mean corpuscular hemoglobin (MCH) in the high-dose senicapoc group compared to the placebo. The low-dose senicapoc caused a significant reduction in the MCH but not MCV when compared to the placebo. There was no significant difference in MCHC between the two intervention arms and the placebo arm. The biochemical markers of hemolysis like lactate dehydrogenase and indirect bilirubin were significantly lower in the senicapoc groups compared to the placebo group. The magnitude of the change was dependent on the dose of senicapoc.</P>
<P>The findings seen in the Phase II senicapoc study were confirmed in the Phase III study where senicapoc was compared to a placebo (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>).</P>
<P>The Gupta paper reported significant improvements in laboratory parameters of red cell dehydration (hemoglobin, reticulocyte count, serum bilirubin and serum zinc level) in the intervention group (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Full blood count</HEADING>
<P>The senicapoc study demonstrated an increase in the hemoglobin level by 0.68 gm/dl in the high-dose senicapoc group compared to the 0.01 gm/dl increase in the placebo group (P &lt; 0.001) (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). There was no significant change in the hemoglobin level when 6 mg of senicapoc was compared to the placebo. There was significant increase in the RBC count with senicapoc compared to the placebo in a dose-dependent manner.</P>
<P>Both the high and low doses of senicapoc resulted in a significant decrease in the percentage and absolute number of reticulocytes (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>).</P>
<P>The above findings were confirmed in the Phase III senicapoc study. There was no significant change in the HbF levels (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>).</P>
<P>Gupta reported that participants in the intervention group had a mean hemoglobin level of 7.9 g/dl compared to 6.8 g/dl in the control group (P &lt; 0.01) (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>). Other outcomes were not reported, and SDs were not given. Again, the authors will be contacted to clarify this information.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Quality of life measures</HEADING>
<P>These measures were not assessed in the Phase II study of senicapoc (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>).</P>
<P>In the Phase III senicapoc study there was no difference in the FACIT-Fatigue scores between the two treatment arms irrespective of the hydroxyurea stratification. Similarly, there was no difference in the number of participants transfused, the number of transfusions or units per participant. The participants on senicapoc spent more days in the hospital compared to those on placebo (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>).</P>
<P>Gupta reported the mean length of hospital stay per crisis in the intervention and control groups respectively was 4.3 and 3.9 days, MD 0.40 (95% CI -0.28 to 1.06), with no significant difference (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>). Days of work lost per crisis were 3.4 in the zinc group and 4.9 in the control group. Although there is a significant reduction in the number of work days lost in the zinc group, MD -1.50 (95% CI -2.24 to -0.76), on average hospital stay was longer in this group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Other sickle-related events</HEADING>
<P>In the Phase II senicapoc study, there was one episode of staphylococcal sepsis in the low-dose senicapoc group and one urinary tract infection in the high-dose senicapoc group (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). There was one report of muscle strain in the high-dose senicapoc group and once case of bronchitis in the placebo group (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>).</P>
<P>In the Phase III senicapoc study there was no significant difference in other sickle cell-related events (pneumonia, asthma, fever, catheter-related infections) between the senicapoc and the placebo groups (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>).</P>
<P>In the zinc study, there were 108 episodes of infection reported in the intervention group compared to 204 in the control group (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Adverse drug reactions</HEADING>
<P>In the Phase II senicapoc study three participants discontinued the study due to adverse events (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). One of the participants in the low-dose senicapoc group had dyspnoea and weakness and two in the high-dose senicapoc group had acute chest syndrome and painful crises. Diarrhea and nausea of mild to moderate intensity were more common in the senicapoc groups compared to the placebo group.</P>
<P>Nausea and urinary tract infections were significantly higher in the senicapoc-treated participants compared to placebo in the Phase III senicapoc study. All other adverse events were similar between the two treatment groups (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>).</P>
<P>The Gupta study states that zinc was well-tolerated with no significant toxicity throughout the study, although it was unclear which potential toxic effects were monitored (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-01-28 14:37:07 +0000" MODIFIED_BY="Tracey Remmington">
<P>Zinc deficiency in sickle cell disease has been shown in observational studies to correlate with disease severity (<LINK REF="REF-Gupta-1987" TYPE="REFERENCE">Gupta 1987</LINK>; <LINK REF="REF-Karayalcin-1974" TYPE="REFERENCE">Karayalcin 1974</LINK>). Laboratory studies have shown that zinc can improve the sickle cell membrane status and antagonise intracellular calcium, and could therefore affect red cell dehydration (<LINK REF="REF-Bennekou-2001" TYPE="REFERENCE">Bennekou 2001</LINK>). The Gupta study included in this review showed a significant reduction in the number of sickle-related events in one and a half years of use in people treated with zinc sulphate (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>). However, lack of data in the publication makes it difficult to analyse the effect on other outcomes, on painful crisis frequency in particular. In addition, changes to hematological indices, which could be used as biomarkers of RBC sickling, were inconclusive. Further research is required to evaluate the effect of zinc on the basic mechanisms of sickle cell disease. Previous studies using zinc also suggest a benefit for other problems in sickle cell disease, including leg ulcers (<LINK REF="REF-Serjeant-1970" TYPE="REFERENCE">Serjeant 1970</LINK>), growth (<LINK REF="REF-Zemel-2001" TYPE="REFERENCE">Zemel 2001</LINK>), infection (<LINK REF="REF-Prasad-1999" TYPE="REFERENCE">Prasad 1999</LINK>) and androgen deficiency in male participants (<LINK REF="REF-Prasad-1981" TYPE="REFERENCE">Prasad 1981</LINK>). However, these studies were not included in the review since they do not consider prevention of vaso-occlusive crises.</P>
<P>Senicapoc (ICA-17043) is a selective and potent blocker of the Gardos channel in the RBC (<LINK REF="REF-Stocker-2003" TYPE="REFERENCE">Stocker 2003</LINK>). The effect of this drug on the markers of hemolysis and hemoglobin level was evaluated in a 12-week, Phase II randomized double-blind study in people with sickle cell disease (<LINK REF="STD-Ataga-2008" TYPE="STUDY">Ataga 2008</LINK>). The findings of this study suggested an increase in the lifespan of the sickle red cells, but there was no difference in the incidence of painful crises. A subsequent Phase III study was terminated early due to the lack of improvement in the vaso-occlusive pain crisis in people with sickle cell disease (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>).</P>
<P>A number of other studies did not satisfy the inclusion criteria, but are still relevant to this review. Cetiedil citrate is believed to act at the Gardos channel, antagonising the calcium-mediated potassium efflux from RBCs, thus affecting red cell hydration and preventing sickling. In two randomized controlled trials investigating this treatment of sickle pain crises, both found it to limit the duration of a pain crisis and reduce the number of sites of pain compared to placebo (<LINK REF="STD-Benjamin-1986" TYPE="STUDY">Benjamin 1986</LINK>; <LINK REF="STD-Cabannes-1983" TYPE="STUDY">Cabannes 1983</LINK>). No studies have tested its use in preventing sickle crises.</P>
<P>Piracetam improves red cell rheology; however, the exact mechanism of this on the red cell membrane is unclear. It was initially believed to inhibit the Gardos channel, but later studies disproved this theory (<LINK REF="REF-Stone-1988" TYPE="REFERENCE">Stone 1988</LINK>; <LINK REF="REF-Stuart-1992" TYPE="REFERENCE">Stuart 1992</LINK>). It has been shown in one randomized controlled trial to decrease the number of pain crises (<LINK REF="STD-Piracetam-Study-1998" TYPE="STUDY">Piracetam Study 1998</LINK>) and in another to have no effect in preventing pain crises (<LINK REF="STD-Alvim-2005" TYPE="STUDY">Alvim 2005</LINK>). For further information, please see the relevant Cochrane Review (<LINK REF="REF-Al-Hajeri-2007" TYPE="REFERENCE">Al Hajeri 2007</LINK>).</P>
<P>Magnesium is known to inhibit the potassium-chlorine ion pump, and observational studies have shown benefits in sickle cell disease.</P>
<P>Sodium cromoglicolate can stabilise erythrocyte membranes by blocking chlorine or calcium channels. In an <I>ex vivo </I>study, two groups of nine children were given sodium cromoglicolate either by the nasal route or inhalation (<LINK REF="STD-Toppet-2000" TYPE="STUDY">Toppet 2000</LINK>). The percentage of sickled cells in the blood of all children significantly decreased, regardless of which group they were assigned to. Further studies are now needed to test the clinical benefit of this agent.</P>
<P>Diltiazem also proved useful in a pilot study which measured sickle pain intensity and duration and various hematological parameters (<LINK REF="STD-Rubio-1992" TYPE="STUDY">Rubio 1992</LINK>). It is a calcium channel blocker and may impact on red cell hydration.</P>
<P>It was been hypothesised that hydroxyurea may increase intrinsic levels of nitric oxide, and this may affect red cell hydration. Effectiveness of hydroxyurea is considered in a different Cochrane Review (<LINK REF="REF-Jones-2001" TYPE="REFERENCE">Jones 2001</LINK>).</P>
<P>Zinc sulphate appears to be of benefit to people with sickle cell disease (<LINK REF="STD-Gupta-1995" TYPE="STUDY">Gupta 1995</LINK>).</P>
<P>However, further research in the form of large well-designed randomized controlled trials is required to fully elucidate the true value in sickle cell disease of drugs which aim to prevent red cell dehydration.</P>
<P>We will continue to run searches to identify any potentially relevant trials; however, we do not plan to update other sections of the review until new trials are published.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-05-02 10:12:52 +0100" MODIFIED_BY="Nikki Jahnke">
<IMPLICATIONS_PRACTICE MODIFIED="2012-05-02 10:12:03 +0100" MODIFIED_BY="Nikki Jahnke">
<P>There is evidence that zinc sulphate is associated with a reduction in pain crises, and also with reductions in other sickle cell-related crises. This was despite the treatment not being associated with an improvement in any of the hematological outcomes. While these results are encouraging, widespread introduction of this agent in the management of people with sickle cell disease is not indicated at present.</P>
<P>Senicapoc clearly improves the red cell survival in a dose-dependent manner. But the improvement in the laboratory measures did not translate into clinical benefits. There was no reduction in the incidence of sickle cell crises with the use of senicapoc. Therefore, currently this drug cannot be used in clinical practice for the prevention of vaso-occlusive crises.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-05-02 10:12:52 +0100" MODIFIED_BY="Nikki Jahnke">
<P>More studies are needed to evaluate the effect of zinc sulphate and of piracetam on the basic mechanisms of sickle cell disease. Further multicenter randomized controlled trials of zinc sulphate in people with sickle cell disease should be conducted. To investigate whether the findings previously reported are consistent and sustained, these future studies should be larger and longer term than the one reported in this review. Senicapoc improved red cell survival and decreased hemolysis. Further studies are needed to ascertain if this drug will be beneficial in some of the other complications of sickle cell disease such as pulmonary hypertension.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to acknowledge the significant contribution made on this review by the original authors - Dr Ceri Hirst and Dr Lucia de Franceschi.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-07-27 12:18:03 +0100" MODIFIED_BY="Nikki Jahnke">
<SUBSECTION>
<HEADING LEVEL="2">Review from Issue 4, 2009</HEADING>
<P>Dr Singh has stepped down from the review team and Dr Nagalla is now the lead author for this review. Together with Dr Ballas, Dr Nagalla has updated this review and acts as guarantor for this and subsequent versions of the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Review from Issue 4, 2007</HEADING>
<P>Dr Singh is now lead author and updated the review with Dr Samir Ballas (co-author). Dr Singh acts as guarantor of the review. Dr Singh reviewed the current literature on piracetam and revised the manuscript with advice from Dr Ballas.</P>
<P>Drs Hirst and de Franceschi have stepped down as active authors on this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Review up to Issue 3, 2007</HEADING>
<P>The review was conceived by the Cochrane Cystic Fibrosis and Genetic Disorders Group and designed by Dr Hirst (née Riddington).</P>
<P>Dr Hirst and the Cochrane Cystic Fibrosis and Genetic Disorders Group conducted searches for relevant studies.</P>
<P>Dr Hirst and Dr de Franceschi screened, appraised and abstracted data for the review. Additional information from authors was sought by Dr Hirst were necessary.</P>
<P>Data entry was performed by Dr Hirst and interpreted by Dr Hirst with advice from the Cochrane Cystic Fibrosis and Genetic Disorders Group.</P>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-11-05 11:30:33 +0000" MODIFIED_BY="Tracey Remmington"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-01-15 11:49:29 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-05-09 11:20:50 +0100" MODIFIED_BY="Nikki Jahnke">
<INCLUDED_STUDIES MODIFIED="2011-11-29 12:46:46 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Ataga-2008" MODIFIED="2009-10-01 14:34:58 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Ataga 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-08-11 02:42:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, et al</AU>
<TI>Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia</TI>
<SO>Blood</SO>
<YR>2008</YR>
<VL>111</VL>
<NO>8</NO>
<PG>3991-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ataga-2011" MODIFIED="2011-11-29 12:46:46 +0000" MODIFIED_BY="[Empty name]" NAME="Ataga 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-11-29 12:46:46 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, et al</AU>
<TI>Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease:  a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)</TI>
<SO>British Journal of Haematology</SO>
<YR>2011</YR>
<VL>153</VL>
<NO>1</NO>
<PG>92-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gupta-1995" NAME="Gupta 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gupta VL, Chaubey BS</AU>
<TI>Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1995</YR>
<VL>43</VL>
<NO>7</NO>
<PG>467-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-05-02 10:33:17 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Adadevoh-1973" NAME="Adadevoh 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Sickling not via membrane effects on dehydration&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adadevoh BK, Isaacs WA</AU>
<TI>The effect of megestrol acetate on sickling</TI>
<SO>American Journal of the Medical Sciences</SO>
<YR>1973</YR>
<VL>265</VL>
<NO>5</NO>
<PG>367-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Adams_x002d_Graves-1997" MODIFIED="2012-05-02 10:23:11 +0100" MODIFIED_BY="Tracey Remmington" NAME="Adams-Graves 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Adams-Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D, et al</AU>
<TI>RheothRx (Poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study</TI>
<SO>Blood</SO>
<YR>1997</YR>
<VL>90</VL>
<NO>5</NO>
<PG>2041-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Adams-Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D</AU>
<TI>Rheothrx (Poloxamer 188) injection for the acute painful episode of sickle cell disease (SCD): a pilot study [abstract]</TI>
<SO>Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program; March 1995</SO>
<YR>1995</YR>
<PG>118</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-05-02 10:23:11 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adams-Graves P, Mauer A</AU>
<TI>RheothRx® (poloxamer 188) injection for the acute painful episode of sickle cell disease</TI>
<SO>Blood</SO>
<YR>1994</YR>
<VL>84</VL>
<NO>Suppl</NO>
<PG>410a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emanuele M, Adams-Graves P, Kedar A, Koshy M, Steinberg R, Veith R, et al</AU>
<TI>RheothRx (Poloxamer 188) lowers serum LDH during an acute painful episode of sickle cell disease [abstract]</TI>
<SO>Blood</SO>
<YR>1996</YR>
<VL>88</VL>
<NO>10 (Suppl 1)</NO>
<PG>13a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akinsulie-2005" MODIFIED="2009-07-08 14:15:31 +0100" MODIFIED_BY="[Empty name]" NAME="Akinsulie 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-08 14:15:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akinsulie AO, Temiye EO, Akanmu AS, Lesi FE, Whyte CO</AU>
<TI>Clinical evaluation of extract of Cajanus cajan (Ciklavit) in sickle cell anaemia</TI>
<SO>Journal of Tropical Pediatrics</SO>
<YR>2005</YR>
<VL>51</VL>
<NO>4</NO>
<PG>200-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Jam_x0027_a-1999" NAME="Al-Jam'a 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Jam'a AH, Al-Dabbous IA, Rafiq MS, Al-Khatti A, Al-Salem AH, Al-Baharna A, et al</AU>
<TI>Isoxsuprine in the treatment of sickle cell painful crises: a double-blind comparative study with narcotic analgesia</TI>
<SO>Annals of Saudi Medicine</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>2</NO>
<PG>97-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alvim-2005" NAME="Alvim 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alvim RC, Viana MB, Pires MA, Franklin HM, Paula MJ, Brito AC, et al</AU>
<TI>Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease</TI>
<SO>Acta Haematologica</SO>
<YR>2005</YR>
<VL>113</VL>
<NO>4</NO>
<PG>228-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ataga-2002" NAME="Ataga 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ataga KI, Orringer EP, Styles L, Vichinsky E, Swerdlow P, Davis GA, et al</AU>
<TI>A phase 1B randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of IC 17043 in patients with sickle cell disease (SCD) [abstract]</TI>
<SO>Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program</SO>
<YR>2002</YR>
<PG>41a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ataga KI, Orringer EP, Styles L, Vichinsky E, Swerdlow P, Davis GA, et al</AU>
<TI>A phase 1B randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of ICA-17043 in patients with sickle cell disease (SCD) [abstract]</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<NO>11 (Part 1 of 2)</NO>
<PG>454a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ayra-1996" NAME="Ayra 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Antisickling action via changing oxygen affinity&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arya R, Rolan PE, Wootton R, Posner J, Bellingham AJ</AU>
<TI>Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia</TI>
<SO>British Journal of Haematology</SO>
<YR>1996</YR>
<VL>93</VL>
<NO>4</NO>
<PG>817-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bartolucci-2009" MODIFIED="2011-11-29 12:51:25 +0000" MODIFIED_BY="Tracey Remmington" NAME="Bartolucci 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-29 12:51:25 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="OTHER">
<AU>Bartolucci P, El Murr T, Roudot-Thoraval F, Habibi A, Santin A, Renaud B, et al</AU>
<TI>A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults</TI>
<SO>Blood</SO>
<YR>2009</YR>
<VL>114</VL>
<NO>18</NO>
<PG>3742-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="93124810"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beatty-2007" MODIFIED="2012-05-02 10:25:38 +0100" MODIFIED_BY="[Empty name]" NAME="Beatty 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-05-02 10:25:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beatty JR, Calamaras DM, Gamerman SE, Nuuhiwa JKB, Schmidt NA</AU>
<TI>The effect of guided imagery on pain in children [abstract]</TI>
<SO>Proceedings of the 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA</SO>
<YR>2007</YR>
<PG>346</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benjamin-1986" MODIFIED="2012-05-02 10:20:14 +0100" MODIFIED_BY="Tracey Remmington" NAME="Benjamin 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-05-02 10:20:14 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benjamin LJ, Berkowitz LR, Orringer E, Mankad VN, Prasad AS, Lewkow LM, et al</AU>
<TI>A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis</TI>
<SO>Blood</SO>
<YR>1986</YR>
<VL>67</VL>
<NO>5</NO>
<PG>1442-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Billet-1989" NAME="Billet 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;no evidence of direct anti-sickling via membrane channels&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Billett HH, Kaul DK, Connel MM, Fabry ME, Nagel RL</AU>
<TI>Pentoxifylline (Trental) has no significant effect on laboratory parameters in sickle cell disease</TI>
<SO>Nouvelle Revue Francaise d'Hematologie</SO>
<YR>1989</YR>
<VL>31</VL>
<NO>6</NO>
<PG>403-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cabannes-1983" NAME="Cabannes 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cabannes R, Sangare A, Cho YW</AU>
<TI>Acute painful sickle-cell crises in children: a double-blind, placebo-controlled evaluation of efficacy and safety of cetiedil</TI>
<SO>Clinical Trials Journal</SO>
<YR>1983</YR>
<VL>20</VL>
<NO>4</NO>
<PG>207-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cabannes-1984" NAME="Cabannes 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;mainly anti-platelet mechanism&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cabannes R, Lonsdorfer J, Castaigne JP, Ondo A, Plassard A, Zohoun I</AU>
<TI>Clinical and biological double-blind-study of Ticlopidine in preventive treatment of sickle cell disease crises</TI>
<SO>Agents and Actions Supplements</SO>
<YR>1984</YR>
<VL>15</VL>
<PG>199-212</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Abood-1997" NAME="De Abood 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;no evidence of a membrane hydration action&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Abood M, de Castillo Z, Guerrero F, Espino M, Austin KL</AU>
<TI>Effect of Depo-Provera® or Microgynon® on the painful crises of sickle cell anemia patients</TI>
<SO>Contraception</SO>
<YR>1997</YR>
<VL>56</VL>
<NO>5</NO>
<PG>313-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Ceulaer-1982" NAME="De Ceulaer 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;no evidence of mechanism of preventing dehydration from cell membrane&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>De Ceulaer K, Gruber C, Hayes R, Serjeant GR</AU>
<TI>Medroxyprogesterone acetate and homozygous sickle cell disease</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>8292</NO>
<PG>229-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>De Ceulaer K, Gruber C, Serjeant G</AU>
<TI>Effect of depo-provera on the haematological and clinical features of homozygous sickle cell disease [abstract]</TI>
<SO>Proceedings of the Commonwealth Caribbean Medical Research Council, 27th Scientific Meeting; 1982 April 14-17; Trinidad and Tobago</SO>
<YR>1982</YR>
<PG>47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Ceulaer-1990" NAME="De Ceulaer 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;no evidence of direct anti-sickling effect via membrane channels&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Ceulaer K, Serjeant GR, Nagel RL, Billett HH, Christakis J, Loukopoulos D, et al</AU>
<TI>Intravenous oxypentifylline and the painful crisis of sickle cell disease</TI>
<SO>Clinical Hemorheology</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>1</NO>
<PG>35-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gail-1982" NAME="Gail 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Urea-&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gail M, Beach J, Dark A, Lewis R, Morrow H</AU>
<TI>A double-blind randomized trial of low-dose urea to prevent sickle cell crises</TI>
<SO>Journal of Chronic Diseases</SO>
<YR>1982</YR>
<VL>35</VL>
<NO>2</NO>
<PG>151-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gladwin-2011" MODIFIED="2011-11-29 12:56:04 +0000" MODIFIED_BY="Tracey Remmington" NAME="Gladwin 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-11-29 12:56:04 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="OTHER">
<AU>Gladwin MT, Kato GJ, Weiner D, Onyekwere OC, Dampier C, Hsu L, et al</AU>
<TI>Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2011</YR>
<VL>305</VL>
<NO>9</NO>
<PG>893-902</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="93124810"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godeau-2003" MODIFIED="2012-05-02 10:28:09 +0100" MODIFIED_BY="Tracey Remmington" NAME="Godeau 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-05-02 10:21:58 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godeau B, Roudet-Thoraval F, Havivi A, Elmur T, Bachir D, Paul M, et al</AU>
<TI>Assessment of ketoprofen for acute vaso-occlusive crisis in adult patients with sickle cell disease. A randomized double blind monocentric study [abstract]</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>102</VL>
<NO>11</NO>
<PG>2824a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isaacs-1971" NAME="Isaacs 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isaacs WA, Effiong CE, Ayeni O</AU>
<TI>Steroid treatment in the prevention of painful episodes in sickle-cell disease</TI>
<SO>Lancet</SO>
<YR>1972</YR>
<VL>1</VL>
<NO>7750</NO>
<PG>570-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isaacs WA</AU>
<TI>The effect of certain lipid substances on sickling</TI>
<SO>Acta Haematologica</SO>
<YR>1971</YR>
<VL>45</VL>
<NO>4</NO>
<PG>259-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Jacobson-1997" NAME="Jacobson 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jacobson SJ, Kopecky EA, Joshi P, Babul N</AU>
<TI>Randomised trial of oral morphine for painful episodes of sickle-cell disease in children</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<NO>9088</NO>
<PG>1358-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kopesky EA, Jacobson S, Joshi P, Koren G</AU>
<TI>Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>3</NO>
<PG>140-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lonsdorfer-1984" NAME="Lonsdorfer 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;mainly anti-platelet mechanism&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lonsdorfer J, Castaigne JP, Lenormand E, Otayeck A, Bogui P, Dosso Y, et al</AU>
<TI>Beneficial effects of Ticlopidine on cardiopulmonary function of sickle cell patients not in crisis</TI>
<SO>Agents and Actions Supplements</SO>
<YR>1984</YR>
<VL>15</VL>
<PG>213-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmood-1969" NAME="Mahmood 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahmood A</AU>
<TI>A double-blind trial of a phenothiazine compound in the treatment of clinical crisis of sickle cell anaemia</TI>
<SO>British Journal of Haematology</SO>
<YR>1969</YR>
<VL>16</VL>
<NO>1</NO>
<PG>181-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manion-2001" NAME="Manion 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Manion C, Parkhurst JB, Ogle B, Johnson A, Edmundson A</AU>
<TI>Aspartame inhibits hypoxia-induced sickling of erythrocytes in patients with sickle cell disease [abstract]</TI>
<SO>Proceedings of the 24th Annual Meeting of the National Sickle Cell Disease Program</SO>
<YR>2000</YR>
<PG>172a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Manion CV, Howard J, Ogle B, Parkhurst J, Edmundson A</AU>
<TI>Aspartame effect in sickle cell anemia</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2001</YR>
<VL>69</VL>
<NO>5</NO>
<PG>346-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manrique-1987" NAME="Manrique 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;pentoxifylline - no evidence of direct anti-sickling via membrane channels&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manrique RV</AU>
<TI>Placebo controlled double-blind study of pentoxifylline in sickle cell disease patients</TI>
<SO>Journal of Medicine</SO>
<YR>1987</YR>
<VL>18</VL>
<NO>5&amp;6</NO>
<PG>277-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orringer-1991" MODIFIED="2012-05-02 10:29:47 +0100" MODIFIED_BY="Tracey Remmington" NAME="Orringer 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-05-02 10:29:47 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Orringer E, Huffman J, Johnson A, Jones S, Whitney J, Brockenbrough S, et al</AU>
<TI>A clinical study of the safety, pharmacokinetics and pharmacodynamics of intravenous infusions of 12C79 in sickle cell disease patients not in crisis [abstract]</TI>
<SO>Proceedings of the 16th Annual Meeting of the National Sickle Cell Disease Program; March 1991</SO>
<YR>1991</YR>
<PG>112</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orringer EP, Binder EA, Thomas RP, Blythe DS, Bustrack JA, Schroeder DH, et al</AU>
<TI>Phase 1 study of BW 12C in sickle cell disease (SCD) patients not in crisis [abstract]</TI>
<SO>Blood</SO>
<YR>1988</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>69a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Orringer EP, Binder EA, Thomas RP, Blythe DS, Bustrack JA, Schroeder DH, et al</AU>
<TI>Phase I study of 12C79 in sickle cell disease (SCD) patients not in crisis [abstract]</TI>
<SO>Proceedings of the 14th Annual Meeting of the National Sickle Cell Disease Program</SO>
<YR>1989</YR>
<PG>57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Osamo-1981" NAME="Osamo 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Osamo NO, Photiades DP, Famodu AA</AU>
<TI>Therapeutic effect of aspirin in sickle cell anaemia</TI>
<SO>Acta Haematologica</SO>
<YR>1981</YR>
<VL>66</VL>
<NO>2</NO>
<PG>102-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oski-1968" NAME="Oski 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oski F, Call FL, Lessen L</AU>
<TI>Failure of promazine HCl to prevent the painful episodes in sickle cell anemia</TI>
<SO>Journal of Pediatrics</SO>
<YR>1968</YR>
<VL>73</VL>
<NO>2</NO>
<PG>265-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oyewo-1987" NAME="Oyewo 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oyewo EA</AU>
<TI>Therapeutic effect of diflusinal as prophylaxis in sickle cell anaemia</TI>
<SO>Clinical Trials Journal</SO>
<YR>1987</YR>
<VL>24</VL>
<NO>3</NO>
<PG>249-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pace-2003" NAME="Pace 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pace BS, Shartava A, Pack-Mabien A, Mulekar M, Ardia A, Goodman SR</AU>
<TI>Effects of N-acetylcysteine on dense cell formation in sickle cell disease</TI>
<SO>American Journal of Hematology</SO>
<YR>2003</YR>
<VL>73</VL>
<NO>1</NO>
<PG>26-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichard-1987" NAME="Pichard 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;pentoxifylline: no evidence of direct anti-sickling via membrane channels&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichard E, Duflo B, Coulibaly S, Mariko B, Monsempes JL, Traore HA, et al</AU>
<TI>Effectiveness of treatment during osteoarticular pain crises in drepanocytosis; based on the example of pentoxifylline</TI>
<TO>Evaluation de L'efficacite des traitements au cours des crises douloureuses osteo-articulaires de la drepanocytose exemple de la pentoxifylline</TO>
<SO>Bulletin de la Societe de Pathologie Exotique et de ses Filiales (Paris)</SO>
<YR>1987</YR>
<VL>80</VL>
<NO>5</NO>
<PG>834-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piracetam-Study-1998" MODIFIED="2012-05-02 10:31:42 +0100" MODIFIED_BY="Tracey Remmington" NAME="Piracetam Study 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-05-02 10:31:42 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>El-Hazmi AF, Warsy AS, Al-Fawaz I, Farid M, Refai S, Opawoye AD, et al</AU>
<TI>Piracetam in the treatment of sickle cell disease [abstract]</TI>
<SO>Proceedings of the 20th Annual Meeting of the National Sickle Cell Disease Program</SO>
<YR>1995</YR>
<PG>162a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Hazmi MAF, Warsy AS, Al-Fawaz I, Opawoye AD, Abu Taleb H, Howsawi Z, et al</AU>
<TI>Piracetam is useful in the treatment of children with sickle cell disease</TI>
<SO>Acta Haematologica</SO>
<YR>1996</YR>
<VL>96</VL>
<NO>4</NO>
<PG>221-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The Piracetam Study Group</AU>
<TI>Piracetam for the treatment of sickle cell disease in children - a double blind test</TI>
<SO>Saudi Medical Journal</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>1</NO>
<PG>22-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poflee-1991" NAME="Poflee 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;pentoxifylline - no evidence of direct anti-sickling via membrane channels&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poflee VW, Gupta OP, Jain AP, Jajoo UN</AU>
<TI>Haemorheological treatment of painful sickle cell crises: use of pentoxifylline</TI>
<SO>Journal of the Association of Physicians India</SO>
<YR>1991</YR>
<VL>39</VL>
<NO>8</NO>
<PG>608-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qari-2007" MODIFIED="2009-07-08 14:16:53 +0100" MODIFIED_BY="[Empty name]" NAME="Qari 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-08 14:16:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qari MH, Aljaouni SK, Alardawi MS, Fatani H, Alsayes FM, Zografos P, et al</AU>
<TI>Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2007</YR>
<VL>98</VL>
<NO>2</NO>
<PG>392-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubio-1992" NAME="Rubio 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubio A, Cox C, Weintraub M</AU>
<TI>Prediction of diltiazem plasma concentration curves from limited measurements using compliance data</TI>
<SO>Clinical Pharmacokinetics</SO>
<YR>1992</YR>
<VL>22</VL>
<NO>3</NO>
<PG>238-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubio A, Weintraub M</AU>
<TI>Scoring system in a pilot effectiveness study of patients with sickle cell anemia</TI>
<SO>Journal of Clinical Research and Pharmacoepidemiology</SO>
<YR>1992</YR>
<VL>6</VL>
<PG>47-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Semple-1984" NAME="Semple 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Ticlopidine- mainly anti-platelet mechanism&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Semple MJ, Al-Hasani SF, Kioy P, Savidge GF</AU>
<TI>A double-blind trial of Ticlopidine in sickle cell disease</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1984</YR>
<VL>51</VL>
<NO>3</NO>
<PG>303-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silva_x002d_Pinto-2007" MODIFIED="2009-07-08 14:17:06 +0100" MODIFIED_BY="[Empty name]" NAME="Silva-Pinto 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-08 14:17:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silva-Pinto AC, Carrara RC, Oliveira VC, Palma PV, Campos AD, Zago MA, Covas DT</AU>
<TI>Hydroxyurea treatment of sickle cell diseases causes megaloblastic transformation of the bone marrow that is responsible for the increase of the mean corpuscular volume [abstract]</TI>
<SO>Haematologica</SO>
<YR>2007</YR>
<VL>92</VL>
<NO>Suppl 1</NO>
<PG>298</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teuscher-1988" NAME="Teuscher 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;pentoxifylline - no evidence of direct anti-sickling via membrane channels&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teuscher T, Weil Von Der Ahe C, Baillod P, Holzer B</AU>
<TI>Double blind randomised clinical trial of pentoxiphyllin in vaso-occlusive sickle cell crisis</TI>
<SO>Tropical and Geographical Medicine</SO>
<YR>1989</YR>
<VL>41</VL>
<NO>4</NO>
<PG>320-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toppet-2000" NAME="Toppet 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toppet M, Fall ABK, Ferster A, Fondu P, Melot C, Vanhaelen-Fastre R, et al</AU>
<TI>Antisickling activity of sodium cromoglicate in sickle-cell disease [letter]</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9226</NO>
<PG>309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Urea-Trial-1974" NAME="Urea Trial 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Urea-&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooperative Urea Trials Group</AU>
<TI>Clinical trials of therapy for sickle cell vaso-occlusive crises</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1974</YR>
<VL>228</VL>
<NO>9</NO>
<PG>1120-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Urea-Trial-2-1974" NAME="Urea Trial 2 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Urea-&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooperative Urea Trials Group</AU>
<TI>Treatment of sickle cell crisis with urea in invert sugar. A controlled trial.</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1974</YR>
<VL>228</VL>
<NO>9</NO>
<PG>1125-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Urea-Trial-3-1974" NAME="Urea Trial 3 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Urea-&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooperative Urea Trials Group</AU>
<TI>Controlled clinical trials and cooperative study of intravenously administered alkali</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1974</YR>
<VL>228</VL>
<NO>9</NO>
<PG>1129-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uzun-2010" MODIFIED="2011-11-29 12:56:37 +0000" MODIFIED_BY="Tracey Remmington" NAME="Uzun 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-11-29 12:56:37 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="OTHER">
<AU>Uzun B, Kekec Z, Gurkan E</AU>
<TI>Efficacy of tramadol vs meperidine in vasoocclusive sickle cell crisis</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>4</NO>
<PG>445-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="93124810"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallen-2007" MODIFIED="2009-10-25 17:26:46 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Wallen 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-10-25 17:26:46 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wallen GR, Handel D, Mendoza J, Chestnut W, Nichols J, Yates J, et al</AU>
<TI>A randomized pilot study exploring hypnosis as a pain and symptom management strategy in patients with sickle cell disease [abstract]</TI>
<SO>35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA.</SO>
<YR>2007</YR>
<PG>261</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wambebe-2001" NAME="Wambebe 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fonnebo V</AU>
<TI>Indigenous Nigerian medicinal plants may be useful in the management of sickle-cell disorder</TI>
<SO>Focus on Alternative and Complementary Therapies</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>2</NO>
<PG>146</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wambebe C, Khamofu H, Momoh JAF, Ekpeyong M, Audu BS, Njoku OS, et al</AU>
<TI>Double-blind, placebo-controlled, randomised cross-over clinical trial of Niprisan in patients with sickle cell disorder</TI>
<SO>Phytomedicine</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>4</NO>
<PG>252-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wambebe C</AU>
<TI>Chemistry and clinical evaluation of NIPRISAN in patients with sickle cell anemia [abstract]</TI>
<SO>Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program</SO>
<YR>2002</YR>
<PG>46a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wambebe CO, Bamgboye EA, Badru BO, Khamofu H, Momoh JA, Ekpeyong M, et al</AU>
<TI>Efficacy of niprisan in the prophylactic management of patients with sickle cell disease</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>1</NO>
<PG>26-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiner-2002" MODIFIED="2009-07-27 11:48:31 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Weiner 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-07-27 11:45:48 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiner DL, Hibberd PL, Betit P, Botelho CA, Cooper AB, Brugnara C</AU>
<TI>Inhaled nitric oxide for treatment of acute vaso-occlusive crisis in sickle cell disease [abstract]</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<NO>11 Pt 1</NO>
<PG>11a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-08 14:22:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiner DL, Hibberd PL, Betit P, Brugnara C</AU>
<TI>Effectiveness and safety of inhaled nitric oxide for the treatment of vaso-occlusive crisis in pediatric sickle cell disease [abstract]</TI>
<SO>Pediatric Research</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>4 Suppl</NO>
<PG>86A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-27 11:48:31 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C</AU>
<TI>Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>9</NO>
<PG>1136-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wynn-2007" MODIFIED="2009-08-11 02:44:12 +0100" MODIFIED_BY="[Empty name]" NAME="Wynn 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-11 02:44:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wynn L, Debenham E, Faughnan L, Martin B, Kelly T, Reed C, et al</AU>
<TI>Recruitment in the baby hug pediatric hydroxyurea phase 3 clinical trial [abstract]</TI>
<SO>35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA.</SO>
<YR>2007</YR>
<PG>245</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zago-1984" MODIFIED="2012-05-02 10:33:17 +0100" MODIFIED_BY="Tracey Remmington" NAME="Zago 1984" YEAR="1984">
<REFERENCE MODIFIED="2012-05-02 10:33:17 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zago MA, Costa FF, Ismael SJ, Tone LG, Bottura C</AU>
<TI>Treatment of sickle cell diseases with aspirin</TI>
<SO>Acta Haematologica</SO>
<YR>1984</YR>
<VL>72</VL>
<NO>1</NO>
<PG>61-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2012-05-09 11:20:50 +0100" MODIFIED_BY="Nikki Jahnke"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-01-15 11:49:29 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-02-16 13:31:58 +0000" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Adrie-2000" NAME="Adrie 2000" TYPE="JOURNAL_ARTICLE">
<AU>Adrie C, Kister J, De Franceschi L, Rouyer-Fessard P, Kieger L, Marden M, et al</AU>
<TI>Nitric oxide restores the erythrocyte density of the SAD mouse model of sickle cell disease [abstract]</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>11</NO>
<PG>Parts 1 and 2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Al-Hajeri-2007" MODIFIED="2012-02-16 13:31:58 +0000" MODIFIED_BY="Tracey Remmington" NAME="Al Hajeri 2007" TYPE="COCHRANE_REVIEW">
<AU>Al Hajeri AA, Fedorowicz Z, Omran A, Tadmouri GO</AU>
<TI>Piracetam for reducing the incidence of painful sickle cell disease crises</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-02-16 13:31:58 +0000" MODIFIED_BY="Tracey Remmington">
<IDENTIFIER MODIFIED="2012-02-16 13:31:58 +0000" MODIFIED_BY="Tracey Remmington" TYPE="DOI" VALUE="10.1002/14651858.CD006111.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ballas-1989" NAME="Ballas 1989" TYPE="JOURNAL_ARTICLE">
<AU>Ballas SK, Dover GJ, Charache S</AU>
<TI>Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo</TI>
<SO>American Journal of Hematology</SO>
<YR>1989</YR>
<VL>32</VL>
<NO>2</NO>
<PG>104-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballas-2000" NAME="Ballas 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ballas SK</AU>
<TI>Hydration of sickle erythrocytes using a naturally occurring sodium ionophore [abstract]</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>11</NO>
<PG>Parts 1 and 2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bennekou-2000" NAME="Bennekou 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bennekou P, Pederson O, Moller A, Christopherses P</AU>
<TI>Volume control in sickle cells is facilitated by novel anion conductance inhibitor NS1652</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>5</NO>
<PG>1842-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bennekou-2001" NAME="Bennekou 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bennekou P, de Franceschi L, Pedersen O, Lian L, Asakura T, Evans G, et al</AU>
<TI>Treatment with NS3623, a novel Cl-conductance blocker, amiliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease</TI>
<SO>Blood</SO>
<YR>2001</YR>
<VL>97</VL>
<NO>5</NO>
<PG>1451-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brugnara-1987" NAME="Brugnara 1987" TYPE="JOURNAL_ARTICLE">
<AU>Brugnara C, Tosteson DC</AU>
<TI>Inhibition of K transport by divalent cations in sickle erythrocytes</TI>
<SO>Blood</SO>
<YR>1987</YR>
<VL>70</VL>
<NO>6</NO>
<PG>1810-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brugnara-1993" NAME="Brugnara 1993" TYPE="JOURNAL_ARTICLE">
<AU>Brugnara C, De Franceschi L, Alper SL</AU>
<TI>Inhibition of Ca2+activated K + transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1993</YR>
<VL>92</VL>
<NO>1</NO>
<PG>520-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brugnara-1995" NAME="Brugnara 1995" TYPE="JOURNAL_ARTICLE">
<AU>Brugnara C</AU>
<TI>Red cell dehydration in pathophysiology and treatment of sickle cell disease</TI>
<SO>Current Opinion in Hematology</SO>
<YR>1995</YR>
<VL>2</VL>
<NO>2</NO>
<PG>132-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brugnara-1996" NAME="Brugnara 1996" TYPE="JOURNAL_ARTICLE">
<AU>Brugnara C, Gee B, Armsby CC, Kurth S, Sakamoto M, Rifai N, et al</AU>
<TI>Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1996</YR>
<VL>97</VL>
<NO>5</NO>
<PG>1227-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Charache-1995" NAME="Charache 1995" TYPE="JOURNAL_ARTICLE">
<AU>Charache S, Terrin M, Moore R, Dover G, Barton F, Eckert S, et al</AU>
<TI>Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>332</VL>
<NO>20</NO>
<PG>1317-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davies-1997" NAME="Davies 1997" TYPE="JOURNAL_ARTICLE">
<AU>Davies SC, Oni L</AU>
<TI>Management of patients with sickle cell disease</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>656-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Franceschi-1994" NAME="de Franceschi 1994" TYPE="JOURNAL_ARTICLE">
<AU>de Franceschi L, Saadane N, Trudel M, Alper S L, Brugnara C, Beuzard Y</AU>
<TI>Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease.</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1994</YR>
<VL>93</VL>
<NO>4</NO>
<PG>1670-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2009-10-25 17:18:55 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gibson-1998" NAME="Gibson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gibson X A, Shartava A, McIntyre J, Monteiro C A, Zhang Y, Shah A, et al</AU>
<TI>The efficacy of reducing agents or antioxidants in blocking the formation of dense cells and irreversibly sickled cells in vitro</TI>
<SO>Blood</SO>
<YR>1998</YR>
<VL>91</VL>
<NO>11</NO>
<PG>4373-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gibson-2000" NAME="Gibson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gibson JS, Stewart GW, Ellory JC</AU>
<TI>Effect of dimethyl adipimidate on K+ transport and shape change in red blood cells from sickle cell patients</TI>
<SO>FEBS Letters</SO>
<YR>2000</YR>
<VL>480</VL>
<NO>2-3</NO>
<PG>179-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gini-1987" NAME="Gini 1987" TYPE="JOURNAL_ARTICLE">
<AU>Gini EK, Sonnet J</AU>
<TI>Use of piracetam improves sickle cell deformability in vitro and in vivo</TI>
<SO>Journal of Clinical Pathology</SO>
<YR>1987</YR>
<VL>40</VL>
<NO>1</NO>
<PG>99-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gupta-1987" NAME="Gupta 1987" TYPE="BOOK_SECTION">
<AU>Gupta VL, Chaubey BS</AU>
<TI>Red blood cell survival, zinc deficiency and efficacy of zinc therapy in sickle cell disease</TI>
<SO>Thalassemia: pathophysiology and management, part A</SO>
<YR>1987</YR>
<VL>23</VL>
<NO>5</NO>
<PG>477-83</PG>
<ED>Fucharoen S, Rowley PT, Paul NW</ED>
<PB>Alan R Liss Inc</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hankins-2008" MODIFIED="2009-09-17 10:39:22 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Hankins 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hankins JS, Wynn LW, Brugnara C, Hillery CA, Li CS, Wang WC</AU>
<TI>Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia.</TI>
<SO>British Journal of Haematology</SO>
<YR>2008</YR>
<VL>140</VL>
<NO>1</NO>
<PG>80-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hickman-1999" NAME="Hickman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hickman M, Modell B, Greengross P, Chapman C, Layton M, Falconer S, et al</AU>
<TI>Mapping the prevalence of sickle cell disease and beta thalassaemia in England: estimating and validating ethnic-specific rates</TI>
<SO>British Journal of Haematology</SO>
<YR>1999</YR>
<VL>104</VL>
<NO>4</NO>
<PG>860-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-09-14 15:14:57 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2001" MODIFIED="2012-02-16 13:31:17 +0000" MODIFIED_BY="Tracey Remmington" NAME="Jones 2001" TYPE="COCHRANE_REVIEW">
<AU>Jones AP, Davies SC, Olujohungbe A</AU>
<TI>Hydroxyurea for sickle cell disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-02-16 13:31:17 +0000" MODIFIED_BY="Tracey Remmington">
<IDENTIFIER MODIFIED="2012-02-16 13:31:17 +0000" MODIFIED_BY="Tracey Remmington" TYPE="DOI" VALUE="10.1002/14651858.CD002202"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Karayalcin-1974" NAME="Karayalcin 1974" TYPE="JOURNAL_ARTICLE">
<AU>Karayalcin G, Rosner F, Kim KY, Chandra P</AU>
<TI>Plasma-zinc in sickle cell-anaemia [letter]</TI>
<SO>Lancet</SO>
<YR>1974</YR>
<VL>1</VL>
<NO>7850</NO>
<PG>217</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leikin-1989" NAME="Leikin 1989" TYPE="JOURNAL_ARTICLE">
<AU>Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W</AU>
<TI>Mortality in children and adolescents with sickle cell disease</TI>
<SO>Pediatrics</SO>
<YR>1989</YR>
<VL>84</VL>
<NO>3</NO>
<PG>500-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prasad-1981" NAME="Prasad 1981" TYPE="JOURNAL_ARTICLE">
<AU>Prasad AS, Abbasi AA, Rabbani P, DuMouchelle E</AU>
<TI>Effect of zinc supplementation on serum testosterone level in adult male sickle cell anemia subjects</TI>
<SO>American Journal of Hematology</SO>
<YR>1981</YR>
<VL>10</VL>
<NO>2</NO>
<PG>119-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prasad-1999" NAME="Prasad 1999" TYPE="JOURNAL_ARTICLE">
<AU>Prasad AS, Beck FWJ, Kaplan J, Chandrasekar PH, Ortega J, Fitzgerald JT, et al</AU>
<TI>Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD)</TI>
<SO>American Journal of Hematology</SO>
<YR>1999</YR>
<VL>61</VL>
<NO>3</NO>
<PG>194-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Qureshi-2000" NAME="Qureshi 2000" NOTES="&lt;p&gt;no page number, checked, not on medline&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Qureshi MA, Gugnani MK, Swerdlow PS, Girgis RE</AU>
<TI>Decreased exhaled nitric oxide (NO) in patients with sickle cell disease [abstract]</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>11 (Pt 1 and 2)</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rivera-2000" NAME="Rivera 2000" TYPE="CONFERENCE_PROC">
<AU>Rivera A, Brugnara C</AU>
<TI>Vaso-active molecules modulate Gardos channel activity and hydration state of normal and sickle erythrocytes</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>11 (Pt 1 and 2)</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Romero-2000" NAME="Romero 2000" NOTES="&lt;p&gt;no page number, checked not on medline&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Romero JR, Suzuka SM, Nagel RL, Fabry ME</AU>
<TI>Arginine supplementation of sickle transgenic mice: effects on red cell density and potassium transport [abstract]</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>11 (Pt 1 and 2)</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Romero-2002" NAME="Romero 2002" TYPE="JOURNAL_ARTICLE">
<AU>Romero JR, Suzuka SM, Nagel RL, Fabry ME</AU>
<TI>Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>99</VL>
<NO>4</NO>
<PG>1103-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serjeant-1970" NAME="Serjeant 1970" TYPE="JOURNAL_ARTICLE">
<AU>Serjeant GR, Galloway RE, Gueri MC</AU>
<TI>Oral zinc sulphate in sickle-cell ulcers</TI>
<SO>Lancet</SO>
<YR>1970</YR>
<VL>2</VL>
<NO>7679</NO>
<PG>891-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serjeant-1992" NAME="Serjeant 1992" TYPE="BOOK">
<AU>Serjeant GR</AU>
<SO>Sickle cell disease</SO>
<YR>1992</YR>
<EN>2nd</EN>
<PB>Oxford Medical Publications</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stocker-2000" NAME="Stocker 2000" NOTES="&lt;p&gt;no page number, checked not on medline&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Stocker J, De Franceschi L, McNaughton-Smith G, Brugnara C</AU>
<TI>A novel Gardos channel inhibitor, ICA-17043, prevents red blood cell dehydration in vitro and in a mouse model (SAD) of sickle cell disease [abstract]</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>11 (Pt 1 and 2)</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stocker-2003" MODIFIED="2009-07-20 20:59:50 +0100" MODIFIED_BY="[Empty name]" NAME="Stocker 2003" TYPE="JOURNAL_ARTICLE">
<AU>Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C</AU>
<TI>ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>101</VL>
<NO>6</NO>
<PG>2412-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stone-1988" NAME="Stone 1988" TYPE="JOURNAL_ARTICLE">
<AU>Stone PCW, Chalder SM, Stuart J</AU>
<TI>Action of piracetam on cation flux and deformability of sickle cells</TI>
<SO>Clinical Hemorheology</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>5</NO>
<PG>779-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stuart-1990" NAME="Stuart 1990" TYPE="JOURNAL_ARTICLE">
<AU>Stuart J, Stone PCW, Nash GB, Ellory JC</AU>
<TI>Effect of Piracetam on Ca2+-induced K+ efflux from sickle cells</TI>
<SO>Clinical Hemorheology</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>5</NO>
<PG>535-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stuart-1992" NAME="Stuart 1992" TYPE="JOURNAL_ARTICLE">
<AU>Stuart J</AU>
<TI>Rheological consequences of sickle-cell dehydration</TI>
<SO>Clinical Hemorheology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>2</NO>
<PG>203-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zemel-2001" NAME="Zemel 2001" TYPE="CONFERENCE_PROC">
<AU>Zemel B, Kawchak D, Fung E, Ohene-Frempong K, Stallings V</AU>
<TI>Zinc supplementation and linear growth in children with sickle cell disease: a pilot study [abstract]</TI>
<SO>Proceedings of the 25th Annual Meting of the National Sickle Cell Disease Program; April 2001; New York</SO>
<YR>2001</YR>
<PG>Abst #232</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-01-15 10:20:16 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Nagalla-2010" MODIFIED="2012-05-02 10:19:24 +0100" MODIFIED_BY="Tracey Remmington" NAME="Nagalla 2010" TYPE="COCHRANE_REVIEW">
<AU>Nagalla S, Ballas SK</AU>
<TI>Drugs for preventing red blood cell dehydration in people with sickle cell disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-05-02 10:19:24 +0100" MODIFIED_BY="Tracey Remmington">
<IDENTIFIER MODIFIED="2012-05-02 10:19:24 +0100" MODIFIED_BY="Tracey Remmington" TYPE="DOI" VALUE="10.1002/14651858.CD003426.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nagalla-2012" MODIFIED="2015-01-15 10:20:16 +0000" MODIFIED_BY="[Empty name]" NAME="Nagalla 2012" TYPE="COCHRANE_REVIEW">
<AU>Nagalla S, Ballas SK</AU>
<TI>Drugs for preventing red blood cell dehydration in people with sickle cell disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2015-01-15 10:20:16 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-01-15 10:20:16 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003426.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Riddington-2002" MODIFIED="2012-02-16 13:34:26 +0000" MODIFIED_BY="Tracey Remmington" NAME="Riddington 2002" TYPE="COCHRANE_REVIEW">
<AU>Riddington C, De Franceschi L</AU>
<TI>Drugs for preventing red blood cell dehydration in people with sickle cell disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-02-16 13:34:26 +0000" MODIFIED_BY="Tracey Remmington">
<IDENTIFIER MODIFIED="2012-02-16 13:34:26 +0000" MODIFIED_BY="Tracey Remmington" TYPE="DOI" VALUE="10.1002/14651858.CD003426.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singh-2007" MODIFIED="2012-05-02 10:17:58 +0100" MODIFIED_BY="Tracey Remmington" NAME="Singh 2007" TYPE="COCHRANE_REVIEW">
<AU>Singh PC, Ballas SK</AU>
<TI>Drugs for preventing red blood cell dehydration in people with sickle cell disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-05-02 10:17:58 +0100" MODIFIED_BY="Tracey Remmington">
<IDENTIFIER MODIFIED="2012-05-02 10:17:55 +0100" MODIFIED_BY="Tracey Remmington" TYPE="DOI" VALUE="10.1002/14651858.CD003426.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2015-01-15 11:49:29 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Al_x002d_Nood-2011" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Al-Nood 2011" NOTES="&lt;p&gt;Ashley Jones [08/02/2012][][]&lt;/p&gt;" NOTES_MODIFIED="2015-01-15 10:22:14 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Al-Nood HA, Al-Khawlani MM, Al-Akwa A</AU>
<TI>Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients</TI>
<SO>Hemoglobin</SO>
<YR>2011</YR>
<VL>35</VL>
<NO>1</NO>
<PG>13-21</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="848863"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000010540"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alvarez-2013" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Alvarez 2013" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, et al</AU>
<TI>Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial</TI>
<SO>American Journal of Hematology</SO>
<YR>2013</YR>
<VL>88</VL>
<NO>11</NO>
<PG>932-8</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="963136"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000520"/>
<IDENTIFIER TYPE="PUBMED" VALUE="23861242"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aygun-2011" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Aygun 2011" TYPE="CONFERENCE_PROC">
<AU>Aygun B, Mortier NA, Kesler K, Schultz WH, Alvarez OA, Rogers ZR, et al</AU>
<TI>Therapeutic phlebotomy in children with sickle cell anemia, stroke, and iron overload: the SWiTCH experience [abstract]</TI>
<SO>53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California.</SO>
<YR>2011</YR>
<PG>Abstract no: 1044</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="848810"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000004118"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Badaki_x002d_Makun-2014" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Badaki-Makun 2014" TYPE="JOURNAL_ARTICLE">
<AU>Badaki-Makun O, Scott JP, Panepinto JA, Casper TC, Hillery CA, Dean JM, et al</AU>
<TI>Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: methodological issues of a randomized controlled trial</TI>
<SO>Pediatric Blood &amp; Cancer</SO>
<YR>2014</YR>
<VL>61</VL>
<NO>6</NO>
<PG>1049-54</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000731"/>
<IDENTIFIER TYPE="PUBMED" VALUE="24443249"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barrett-2012" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Barrett 2012" TYPE="JOURNAL_ARTICLE">
<AU>Barrett MJ, Cronin J, Murphy A, McCoy S, Hayden J, an Fhaili S, et al</AU>
<TI>Intranasal fentanyl versus intravenous morphine in the emergency department treatment of severe painful sickle cell crises in children: study protocol for a randomised controlled trial</TI>
<SO>Trials</SO>
<YR>2012</YR>
<VL>13</VL>
<PG>74</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="859794"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000732"/>
<IDENTIFIER TYPE="PUBMED" VALUE="22647439"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Daak-2013" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Daak 2013" TYPE="JOURNAL_ARTICLE">
<AU>Daak AA, Ghebremeskel K, Hassan Z, Attallah B, Azan HH, Elbashir MI, et al</AU>
<TI>Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2013</YR>
<VL>97</VL>
<NO>1</NO>
<PG>37-44</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="841628"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000011166"/>
<IDENTIFIER TYPE="PUBMED" VALUE="23193009"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dampier-2010" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Dampier 2010" TYPE="JOURNAL_ARTICLE">
<AU>Dampier C, Smith WR, Wager C, Bell M, Eckman JR, Hsu LL, et al</AU>
<TI>Initial experience with the IMPROVE trial- a phase III analgesic trial for hospitalized sickle cell painful episodes [abstract]</TI>
<SO>Blood</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>21</NO>
<PG>Abstract no: 2667</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000690"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dampier-2011" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Dampier 2011" TYPE="JOURNAL_ARTICLE">
<AU>Dampier C, Smith WR, Wager C, Bell M, Eckman JR, Hsu LL, et al</AU>
<TI>Initial experience with the IMPROVE trial-a phase III analgesic trial for hospitalized sickle cell painful episodes [abstract]</TI>
<SO>Blood</SO>
<YR>2011</YR>
<VL>118</VL>
<NO>21</NO>
<PG>Abstract no: 2667</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="998096"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000689"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dampier-2013" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Dampier 2013" TYPE="JOURNAL_ARTICLE">
<AU>Dampier CD, Smith WR, Wager CG, Kim HY, Bell MC, Miller ST, et al</AU>
<TI>IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies</TI>
<SO>Clinical Trials (London, England)</SO>
<YR>2013</YR>
<VL>10</VL>
<NO>2</NO>
<PG>319-31</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="964614"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000709"/>
<IDENTIFIER TYPE="PUBMED" VALUE="23539110"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-De-Ceulaer-1990" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="De Ceulaer 1990" NOTES="&lt;p&gt;Priya Singh [01/05/2002][13/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2015-01-15 10:22:14 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>De Ceulaer K, Serjeant GR, Nagel RL, Billett HH, Christakis J, Loukopoulos D, et al</AU>
<TI>Intravenous oxpentifylline and the painful crisis of sickle cell disease</TI>
<SO>Clinical Hemorheology</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>1</NO>
<PG>35-42</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:12 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="189585"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000000984"/>
<IDENTIFIER TYPE="EMBASE" VALUE="1990101446"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Desai-2013" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Desai 2013" TYPE="JOURNAL_ARTICLE">
<AU>Desai PC, Brittain JE, Jones SK, McDonald A, Wilson DR, Dominik R, et al</AU>
<TI>A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease</TI>
<SO>Thrombosis Research</SO>
<YR>2013</YR>
<VL>132</VL>
<NO>3</NO>
<PG>341-5</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="917688"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000730"/>
<IDENTIFIER TYPE="PUBMED" VALUE="23973010"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jain-2012" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Jain 2012" TYPE="JOURNAL_ARTICLE">
<AU>Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A</AU>
<TI>Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease</TI>
<SO>Hemoglobin</SO>
<YR>2012</YR>
<VL>36</VL>
<NO>4</NO>
<PG>323-32</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="879848"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000522"/>
<IDENTIFIER TYPE="PUBMED" VALUE="22734586"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kwiatkowski-2012" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Kwiatkowski 2012" TYPE="JOURNAL_ARTICLE">
<AU>Kwiatkowski JL, Cohen AR, Garro J, Alvarez O, Nagasubramanian R, Sarnaik S, et al</AU>
<TI>Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention</TI>
<SO>American Journal of Hematology</SO>
<YR>2012</YR>
<VL>87</VL>
<NO>2</NO>
<PG>221-3</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="864015"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000011226"/>
<IDENTIFIER TYPE="PUBMED" VALUE="22120913"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lemanke-2002" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Lemanke 2002" TYPE="CONFERENCE_PROC">
<AU>Lemanke KL, Ranalli M</AU>
<TI>The benefits of massage therapy in enhancing coping in children with sickle cell disease [abstract]</TI>
<SO>The National Sickle Cell Disease Program Annual Meeting Conference Proceedings; 2002 Sept</SO>
<YR>2002</YR>
<PG>173</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="404044"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000002222"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lonsdorfer-1984" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Lonsdorfer 1984" NOTES="&lt;p&gt;Priya Singh [01/05/2002][13/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2015-01-15 10:22:14 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Lonsdorfer J, Castaigne JP, Lenormand E, Otayeck A, Bogui P, Dosso Y, et al</AU>
<TI>Ticlopidine: Quo vadis? Beneficial effects of ticlopidine on cardiopulmonary function of sickle cell patients not in crisis</TI>
<SO>Agents and Actions. Supplements</SO>
<YR>1984</YR>
<VL>15</VL>
<PG>213-8</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:12 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="208649"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000001132"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Myers-1999" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Myers 1999" TYPE="JOURNAL_ARTICLE">
<AU>Myers CD, Robinson ME, Guthrie TH, Lamp SP, Lottenberg R</AU>
<TI>Adjunctive approaches for sickle cell chronic pain</TI>
<SO>Alternative Health Practitioner</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>3</NO>
<PG>203-12</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="448703"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000002368"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Orringer-1989" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Orringer 1989" NOTES="&lt;p&gt;Priya Singh [01/05/2002][13/03/2003][]&lt;/p&gt;" NOTES_MODIFIED="2015-01-15 10:22:14 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="CONFERENCE_PROC">
<AU>Orringer EP, Binder EA, Thomas RP, Blythe DS, Bustrack JA, Schroeder DH, et al</AU>
<TI>Phase 1 study of 12C79 in sickle cell disease (SCD) patients not in crisis [abstract]</TI>
<SO>The National Sickle Cell Disease Program Annual Meeting Conference Proceedings; 1989 April</SO>
<YR>1989</YR>
<PG>57</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:12 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="342180"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000001877"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ortiz-1998" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Ortiz 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ortiz F, Karwa M, Najeebi S, Benjamin L, Aldrich TK</AU>
<TI>Non-invasive ventilatory support shortens the duration of vaso-occlusive crisis in sickle cell disease [abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<NO>3 Suppl</NO>
<PG>A225</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="404056"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000002229"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Osunkwo-2012" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Osunkwo 2012" TYPE="JOURNAL_ARTICLE">
<AU>Osunkwo I, Ziegler TR, Alvarez J, McCracken C, Cherry K, Osunkwo CE, et al</AU>
<TI>High dose vitamin D therapy for chronic pain in children and adolescents with sickle cell disease: results of a randomized double blind pilot study</TI>
<SO>British Journal of Haematology</SO>
<YR>2012</YR>
<VL>159</VL>
<NO>2</NO>
<PG>211-5</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="841960"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000245"/>
<IDENTIFIER TYPE="PUBMED" VALUE="22924607"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sheehan-2012" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Sheehan 2012" TYPE="JOURNAL_ARTICLE">
<AU>Sheehan VA, Howard TA, Sabo A, Nagasaswamy U, Crosby JR, Davis B, et al</AU>
<TI>Genetic predictors of hemoglobin F response to hydroxyurea in sickle cell anemia [abstract]</TI>
<SO>Blood</SO>
<YR>2012</YR>
<VL>120</VL>
<NO>21</NO>
<PG>Abstract no: 241</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="977454"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000531"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ware-2010" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Ware 2010" TYPE="CONFERENCE_PROC">
<AU>Ware RE, Helms RW</AU>
<TI>Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase 3 randomised clinical trial for treatment of children with sickle cell anemia [abstract]</TI>
<SO>52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida.</SO>
<YR>2010</YR>
<PG>Abstract no: 844</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000004122"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ware-2011" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Ware 2011" NOTES="&lt;p&gt;Ceri Hirst [06/10/2011][][]; Ashley Jones [08/02/2012][][]&lt;/p&gt;" NOTES_MODIFIED="2015-01-15 10:22:14 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Ware RE, Helms RW</AU>
<TI>Stroke with transfusions changing to hydroxyurea (SWiTCH)</TI>
<SO>Www.clinicaltrials.gov (www.clinicaltrials.gov)</SO>
<YR>2011</YR>
<PG>ClinicalTrials.gov Identifier: NCT00122980</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="848940"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000010743"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ware-2011a" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Ware 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Ware RE, Schultz WH, Yovetich N, Mortier NA, Alvarez O, Hilliard L, et al</AU>
<TI>Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload</TI>
<SO>Pediatric Blood &amp; Cancer</SO>
<YR>2011</YR>
<VL>57</VL>
<NO>6</NO>
<PG>1011-7</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="806683"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000004123"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ware-2012" MODIFIED="2015-01-15 10:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="Ware 2012" TYPE="JOURNAL_ARTICLE">
<AU>Ware RE, Helms RW</AU>
<TI>Stroke with transfusions changing to hydroxyurea (SWiTCH)</TI>
<SO>Blood</SO>
<YR>2012</YR>
<VL>119</VL>
<NO>17</NO>
<PG>3925-32</PG>
<IDENTIFIERS MODIFIED="2015-01-15 10:22:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="CENTRAL" VALUE="849022"/>
<IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000004120"/>
</IDENTIFIERS>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-01-28 14:31:36 +0000" MODIFIED_BY="Tracey Remmington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-01-28 14:31:36 +0000" MODIFIED_BY="Tracey Remmington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-05-07 13:48:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ataga-2008">
<CHAR_METHODS MODIFIED="2009-11-04 14:36:08 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Phase II, randomized, double-blind, placebo-controlled study. There was a screening phase and a 12-week treatment phase.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-07 13:47:53 +0100" MODIFIED_BY="[Empty name]">
<P>90 sickle cell participants were recruited at 19 medical centers in the USA. The participants were adults aged between 18 and 60 years with at least one episode of sickle cell-related painful crisis 4 weeks prior to the study screening.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-07 13:48:01 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomized to either:</P>
<P>1. high-dose senicapoc: a single 150 mg senicapoc loading dose followed by 10 mg daily maintenance dose;</P>
<P>2. low-dose senicapoc: a single 100 mg senicapoc loading dose followed by 6 mg daily maintenance dose; or</P>
<P>3. placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-07 13:48:08 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy, safety, pharmacokinetic, and pharmacodynamic measures were obtained on day 1 of study, end of week 1 and every 2 weeks until the end of treatment phase.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-28 14:31:36 +0000" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Ataga-2011">
<CHAR_METHODS MODIFIED="2012-02-16 13:27:28 +0000" MODIFIED_BY="[Empty name]">
<P>Phase III randomized, double-blind, placebo-controlled, parallel group study. There was a screening phase, a 52-week treatment phase, and a follow-up evaluation 8 weeks after the end of the study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-28 14:31:36 +0000" MODIFIED_BY="Tracey Remmington">
<P>297 participants were recruited from 75 centers in the USA, Jamaica, Brazil, France, Trinidad and the United Kingdom. Participants aged between 16 and 65 years and had at least 2 episodes of painful crisis within the preceding 12 months that required medical attention were included. Participants on hydroxyurea in preceding 12 months were required to be on a stable dose of the drug prior to inclusion in the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-16 13:28:21 +0000" MODIFIED_BY="[Empty name]">
<P>Participants were randomized to receive (in a 1:1 fashion):</P>
<P>1. senicapoc (loading dose of 20 mg twice daily for 4 days followed by 10 mg daily); or</P>
<P>2. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-27 09:51:41 +0100" MODIFIED_BY="[Empty name]">
<P>The primary end point was the frequency of sickle cell pain crises. TIme to the first second and third acute painful crises was a secondary end point of the study (<LINK REF="STD-Ataga-2011" TYPE="STUDY">Ataga 2011</LINK>). The effect of the drug on markers of hemolysis, hemoglobin, hematocrit, reticulocyte count, red blood cell count and dense erythrocytes was also measured. Quality of life measures were also included.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-04 14:37:51 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Gupta-1995">
<CHAR_METHODS MODIFIED="2009-11-04 14:36:09 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Double-blind, placebo-controlled, randomized controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>145 participants from India with SS disease, aged over 5 years. 15 participants were lost to follow up.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Zinc (oral 220 mg tds) or placebo (identical in appearance). Participants were seen weekly, follow up was for 1.5 years and the data were analysed at the end of the follow-up period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-04 14:37:51 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Sickle related crises: vaso-occlusive; mixed; hemolytic; sequestration; and aplastic. Days in hospital and working days lost.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>IV: intravenous<BR/>SCD: sickle cell disease<BR/>SS: sickle cell anemia<BR/>tds: three times daily<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-05-07 13:49:33 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Adadevoh-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of megestrol acetate. There is no good recent evidence to suggest that sex hormones prevent dehydration of the sickle red cells.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Adams_x002d_Graves-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial of poloxamer 188 - inappropriate mechanism of action for inclusion in this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-08 16:18:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akinsulie-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-08 16:18:40 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of Cajanus cajan. There is no evidence that the anti-sickling effect of the drug is due to a reduction in water loss through the red cell membrane.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Al_x002d_Jam_x0027_a-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial of isoxsurpine in treatment of sickle cell crises - rather than prevention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Alvim-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of piracetam. There is a lack of evidence that the anti-sickling effect of the drug is due to a reduction in water loss through the cell membrane.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ataga-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacokinetic study of ICA 17043, with no measure of clinical outcomes of interest.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ayra-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of tucaresol. Prevents sickling by shifting the oxygen affinity, not through red cell dehydration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-07 13:49:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bartolucci-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-07 13:49:33 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of ketoprofen for treatment of, rather than prevention of, vaso-occlusive crises. Not a study of a drug involved in the prevention of red blood cell dehydration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 02:48:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beatty-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 02:48:12 +0100" MODIFIED_BY="[Empty name]">
<P>Not a study of a drug involved in the prevention of red blood cell dehydration and vaso-occlusive crisis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Benjamin-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of cetiedil citrate. Used in treatment rather than prevention of crises.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Billet-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in water loss through the red cell membrane.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cabannes-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of cetiedil citrate. Used in treatment rather than prevention of crises.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cabannes-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of ticlopidine. Mainly an inhibitor of platelet action, rather than anti-dehydration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Abood-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of Depo-Provera and Microgynon. There is no good evidence to suggest that sex hormones prevent dehydration of the sickle red cells.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Ceulaer-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of medroxyprogesterone acetate. There is no good recent evidence to suggest that sex hormones prevent dehydration of the sickle red cells</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Ceulaer-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in water loss through the red cell membrane.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gail-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of urea. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the sickle red cells.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-29 12:54:52 +0000" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Gladwin-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-29 12:54:52 +0000" MODIFIED_BY="Tracey Remmington">
<P>Not a study of a drug involved in the prevention of red blood cell dehydration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Godeau-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of ketoprofen for treatment, rather than prevention, of vaso-occlusive crises.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Isaacs-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of steroids. There is no good recent evidence to suggest that sex hormones prevent dehydration of the sickle red cells.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jacobson-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Risk analysis using data from a previous RCT, in which morphine was administered in treatment, rather than prevention, of acute chest syndrome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lonsdorfer-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of ticlopidine. Mainly an inhibitor of platelet action, rather than anti-dehydration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahmood-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of a phenothiazine. Used in treatment rather than prevention of crises.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Manion-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacokinetic study of aspartame, with no measure of outcomes of interest.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Manrique-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in water loss through the red cell membrane.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Orringer-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of 12C79, which prevents sickling primarily by increasing oxygen affinity, with possible secondary effects on the potassium-chloride co-transport channels in the red cell membrane.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Osamo-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial of aspirin. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the sickle red cells.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-04 14:36:10 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Oski-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-04 14:36:10 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Study not randomized, looks at promazine chloride.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oyewo-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study of diflusinal, anti-sickling effects not due to red cell dehydration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pace-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Phase II RCT of N-Acetylcysteine for prevention of sickle cell related vaso-occlusion and formation of dense cells. There is insufficient evidence that N-Acetylcysteine acts via red cell dehydration to include this study in the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pichard-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in water loss through the cell membrane.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Piracetam-Study-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of piracetam. There is a lack of evidence that the anti-sickling effect of the drug is due to a reduction in water loss through the cell membrane.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poflee-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in water loss through the cell membrane.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-08 16:35:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qari-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-08 16:35:31 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of tinzaparin. There is no evidence that the anti-sickling effect of the drug is due to a reduction in water loss through the red cell membrane.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rubio-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pharmacokinetic study of diltiazem, with no measure of outcomes of interest.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Semple-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of ticlopidine. Mainly an inhibitor of platelet action, rather than anti-dehydration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-27 12:20:49 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Silva_x002d_Pinto-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-27 12:20:49 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study of hydroxyurea, no measure of clinical outcomes of interest.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Teuscher-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of pentoxifylline. There is no evidence that the anti-sickling effect of the drug is due to a reduction in water loss through the cell membrane.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-04 14:36:11 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Toppet-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-04 14:36:11 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Non-randomized ex-vivo study of sodium cromoglicate, an anti-sickling agent, majority of patients also taking hydroxyurea.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Urea-Trial-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of urea. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the sickle red cells.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Urea-Trial-2-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of urea. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the sickle red cells.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Urea-Trial-3-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of urea. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the sickle red cells.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-29 12:54:09 +0000" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Uzun-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-29 12:54:09 +0000" MODIFIED_BY="Tracey Remmington">
<P>Study of tramadol or meperidine for treatment of, rather than prevention of, vaso-occlusive crises. Not a study of a drug involved in the prevention if red blood cell dehydration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 02:51:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wallen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 02:51:14 +0100" MODIFIED_BY="[Empty name]">
<P>Not a study of a drug involved in the prevention of red blood cell dehydration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wambebe-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT of Niprisan, a naturally occurring compound. There is no evidence that any anti-sickling action is due to a reduction in dehydration of red cells.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-08 16:51:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiner-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-08 16:51:34 +0100" MODIFIED_BY="[Empty name]">
<P>Study of nitric oxide. There is no evidence that the anti-sickling effect of the drug is due to a reduction in water loss through the red cell membrane.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 02:52:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wynn-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 02:52:15 +0100" MODIFIED_BY="[Empty name]">
<P>Study of hydroxyurea, no measure of clinical outcomes of interest.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zago-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial of aspirin. There is no evidence that any anti-sickling action is due to a reduction in dehydration of the sickle red cells.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomized controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-05-09 11:21:19 +0100" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-04-27 09:54:25 +0100" MODIFIED_BY="Nikki Jahnke">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-04-27 09:54:25 +0100" MODIFIED_BY="Nikki Jahnke" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 16:08:21 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Ataga-2008">
<DESCRIPTION>
<P>Centralized randomization protocol using an integrated voice response system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-21 07:27:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ataga-2011">
<DESCRIPTION>
<P>Centralized randomization protocol using an integrated voice response system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-27 09:54:25 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Gupta-1995">
<DESCRIPTION>
<P>New Castle software was used to generate randomization.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-11-21 07:27:12 +0000" MODIFIED_BY="Nikki Jahnke" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 03:43:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ataga-2008">
<DESCRIPTION>
<P>Allocation concealment was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-21 07:27:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ataga-2011">
<DESCRIPTION>
<P>Allocation concealment was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-26 10:02:11 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-1995">
<DESCRIPTION>
<P>Allocation concealment was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-11-21 07:28:16 +0000" MODIFIED_BY="Nikki Jahnke" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Participants</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Clinicians</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Outcome assessors</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 03:45:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ataga-2008">
<DESCRIPTION>
<P>The participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-08-11 03:46:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ataga-2008">
<DESCRIPTION>
<P>The treating physicians were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-08-11 03:47:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ataga-2008">
<DESCRIPTION>
<P>The review committee was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-11-21 07:27:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ataga-2011">
<DESCRIPTION>
<P>The participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-11-21 07:27:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ataga-2011">
<DESCRIPTION>
<P>The treating physicians were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2011-11-21 07:28:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ataga-2011">
<DESCRIPTION>
<P>The review committee was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 03:50:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gupta-1995">
<DESCRIPTION>
<P>The participants were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-08-11 03:50:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gupta-1995">
<DESCRIPTION>
<P>The treating physicians were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-09-14 16:27:36 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-1995">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-11-21 07:29:45 +0000" MODIFIED_BY="Nikki Jahnke" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-04 15:57:05 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Ataga-2008">
<DESCRIPTION>
<P>Modified intent to treat population was used for analysis. Two participants dropped out prior to the first efficacy analysis. A total of ten participants did not complete the study; full reasons for this were given in the published paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-21 07:29:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ataga-2011">
<DESCRIPTION>
<P>Modified intent to treat population was used for analysis. The study had to be terminated prematurely because it was unlikely to meet the primary end point.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-09-14 16:25:43 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-1995">
<DESCRIPTION>
<P>Fifteen, of the 145 participants recruited, dropped out or were lost to follow up, and these are not accounted for in the study publication. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-11-21 07:30:53 +0000" MODIFIED_BY="Nikki Jahnke" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 11:22:42 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Ataga-2008">
<DESCRIPTION>
<P>All outcomes stated in 'Methods' section reported in 'Results'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-21 07:30:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ataga-2011">
<DESCRIPTION>
<P>All outcomes stated in 'Methods' section reported in 'Results'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 11:32:11 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Gupta-1995">
<DESCRIPTION>
<P>All outcomes stated in 'Methods' section reported in 'Results'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-11-21 07:30:50 +0000" MODIFIED_BY="Nikki Jahnke" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-14 17:09:27 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Ataga-2008">
<DESCRIPTION>
<P>No significant differences in the baseline characteristics of the study participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-21 07:30:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ataga-2011">
<DESCRIPTION>
<P>No significant differences in the baseline characteristics of the study participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-26 23:17:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gupta-1995">
<DESCRIPTION>
<P>Little information was given regarding baseline characteristics, including disease severity and medical history of participants, making it difficult to ascertain if the groups were sufficiently similar at the start of the study. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-05-02 10:45:05 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-05-02 10:45:05 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Anti-sickling drug versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-03-16 18:56:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="65" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Anti-sickling drug</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours drug tmt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-16 18:56:13 +0000" MODIFIED_BY="[Empty name]" ORDER="57183" O_E="0.0" SE="0.0" STUDY_ID="STD-Gupta-1995" TOTAL_1="65" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2012-05-02 10:45:05 +0100" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="65" TOTAL_2="65" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of other serious sickle-related complications</NAME>
<GROUP_LABEL_1>Anti-sickling drug</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours drug tmt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Overall</NAME>
<CONT_DATA CI_END="-2.1537523399212257" CI_START="-3.5062476600787744" EFFECT_SIZE="-2.83" ESTIMABLE="YES" MEAN_1="2.46" MEAN_2="5.29" ORDER="57184" SD_1="1.04" SD_2="2.58" SE="0.3450306563859998" STUDY_ID="STD-Gupta-1995" TOTAL_1="65" TOTAL_2="65" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2012-05-02 10:45:05 +0100" MODIFIED_BY="Tracey Remmington" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="130" TOTAL_2="130" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life measures</NAME>
<GROUP_LABEL_1>Anti-sickling drug</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours drug tmt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Hospital stay per crisis (days)</NAME>
<CONT_DATA CI_END="1.061313323542183" CI_START="-0.2613133235421833" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="3.9" ORDER="57185" SD_1="2.2" SD_2="1.6" SE="0.3374109569147894" STUDY_ID="STD-Gupta-1995" TOTAL_1="65" TOTAL_2="65" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Loss of work days/crisis</NAME>
<CONT_DATA CI_END="-0.7641385759770775" CI_START="-2.2358614240229233" EFFECT_SIZE="-1.5000000000000004" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="4.9" ORDER="57186" SD_1="2.18" SD_2="2.1" SE="0.3754464009682341" STUDY_ID="STD-Gupta-1995" TOTAL_1="65" TOTAL_2="65" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>